<div class="docsource_main">Delhi High Court</div>
<div class="doc_title">Sun Pharma Laboratories Ltd vs Intas Pharmaceuticals Ltd on 9 January, 2020</div><pre id="pre_1">     IN THE HIGH COURT OF DELHI AT NEW DELHI

                    Judgment reserved on : 04.10.2018 &amp; 01.08.2019
                                      Date of decision : 09.01.2020

FAO 447/2018
SUN PHARMA LABORATORIES LTD                         ..... Appellant
                          Through      Mr. Sachin Gupta, Ms. Jasleen
                                       Kaur, Ms. Jyoti Mehra, Advs.
                          versus
INTAS PHARMACEUTICALS LTD                           ..... Respondent
                          Through      Mr. Anil Sapra, Sr. Adv. with
                                       Ms. Bitika Sharma, Mr. Kapil
                                       Midha, Mr. Lakshay Kaushik,
                                       Mr. Sarthak Katyal, Ms.
                                       Akanksha Choudhary, Advs.
CORAM:
HON&#x27;BLE MS. JUSTICE ANU MALHOTRA
                            JUDGMENT
</pre><p id="p_1">ANU MALHOTRA, J.
</p>
<p id="p_2">1.    Vide the present appeal FAO 447/2018 under order XLIII Rule
1(r) read with Sections 104 and 151 of the Code of Civil Procedure,
1908, the appellant assails the impugned order dated 17.09.2018 of the
learned ADJ-05 (SE), Saket Court, New Delhi in TM No. 146/2017
vide which the application under Order 39 Rule 1 &amp; 2 of the Code of
Civil Procedure, 1908 filed the appellant i.e. the plaintiff of the said
suit seeking interdiction against the defendant of the suit i.e. the
respondent herein qua use of trademark &#x27;BEVATAS&#x27; on the ground of
similarity / deceptive similarity with its trademark &#x27;BEVETEX&#x27; was



<span class="hidden_text" id="span_1">FAO 447/2018                                                Page 1 of 87</span>
 dismissed.
</p><p id="p_3">2.    The suit filed by the appellant herein as the plaintiff of the TM
No. 146/2017 before the learned Trial Court is one for permanent
injunction, restraining infringement of trade mark, passing off, unfair
competition, rendition of accounts of profits/ damages, delivery up,
etc., which suit is in relation to the same trademark of the appellant
herein bearing registration no. 410744 dated 16.09.1983 being
allegedly infringed by the user of the impugned trademark
&#x27;BEVATAS&#x27; by the respondent herein.
</p><p id="p_4">3.    The appellant herein states that it is a well known medicinal
pharmaceutical company in India and is now ranked as the no.1
pharma company in India in a total of 11 specialties and is the world&#x27;s
4th largest generic pharmaceutical company and provides the best of
class products across 150 countries worldwide and its manufacturing
operations are focussed on producing generics, branded generics,
specially, over-the-counter (OTC) products anti-retrovirals (ARVs),
Active Pharmaceutical Ingredients (APIs) and intermediates in the full
range of dosage forms, including tablets, capsules, injectables,
ointments, creams and liquids etc.
</p><p id="p_5">4.    The appellant herein states that it is the proprietor and owner of
the intellectual proprietary rights of the Sun Pharmaceutical Industries
Limited for the domestic formulation undertaking activities under the
Scheme of Arrangement between Sun Pharmaceutical Industries
Limited and itself, which was approved and sanctioned by the Hon&#x27;ble
High Court of Gujarat and Hon&#x27;ble High Court of Judicature at
Bombay both vide order dated 03.05.2013 in Company Petition No.



<span class="hidden_text" id="span_2">FAO 447/2018                                                Page 2 of 87</span>
 31 of 2013 and Company Scheme Petition No. 283 of 2013.
</p><p id="p_6">5.    The appellant submits that its predecessor Sun Pharmaceutical
Industries Limited in the year 1983 invented a trademark
&#x27;BEVETEX&#x27; and the same is registered vide registration no. 410744
dated 16.09.1983, which trademark is registered for goods for
Medicinal and Pharmaceutical preparations for human use and has
been renewed, is valid and subsisting and has been entered in the
Trade Mark Register.
</p><p id="p_7">6.    The appellant submits that this medicine of the appellant under
the name of &#x27;BEVETEX&#x27; contains Molecule/Salt PACLITAXEL and
is a scheduled drug used for treatment of Breast Cancer, Non-Small
Cell Lung cancer and Pancreatic cancer. The appellant submits that on
account of its registration qua the registered trademark &#x27;BEVETEX&#x27;,
the appellant herein has a statutory right to the exclusive use of its
registered trademark and the use of the same or a deceptive similar
trade mark by an unauthorized person or trader in relation to the
similar kind of goods will constitute infringement of the appellant&#x27;s
right of the exclusive use of the registered trade mark and also to the
provisions of <a href="/doc/1017213/" id="a_1">The Trade Marks Act</a>, 1999. The appellant submits that
it has been selling its medicine under its trade mark &#x27;BEVETEX&#x27;
since the year 2015 and that it has taken efforts to popularize the same
and has expended substantial sums of money on sales promotion and
publicity on the said goods bearing the said trademark and due to
superior quality and high efficacy of its goods, it has acquired
immense reputation and goodwill and that the members of the trade,
public as also the doctors and chemists exclusively associate the said



<span class="hidden_text" id="span_3">FAO 447/2018                                                Page 3 of 87</span>
 trademark with the plaintiff i.e. the appellant herein and its goods and
with none else. The appellant through its plaint had submitted that the
statement of sales and promotional expenses qua &#x27;BEVETEX&#x27; is as
under : -
</p><p id="p_8"> STATEMENT OF SALES AND PROMOTIONAL EXPENSES

      Year              Expenses                     Sales
                  Rs. in Lac (Approx)        Rs. in Lac (Approx)
     2015-16              18.99                     379.97
     2016-17              34.80                     696.09
      Total               53.79                     1076.06


</p><p id="p_9">7.    The appellant herein submits that it being the proprietor of the
trade mark &#x27;BEVETEX&#x27; which has acquired formidable goodwill,
reputation and distinctiveness vis-a-vis such goods and that the
appellant herein has the exclusive right to use the said trademark and
ought to be protected by this Court against imitation, confusion,
deception, dilution and unfair competition by competitors in trade.
</p><p id="p_10">8.    It has been submitted through the plaint that the defendant i.e.
the respondent to the present appeal i.e. Intas Pharmaceuticals Limited
is a company under the <a href="/doc/1353758/" id="a_2">Companies Act</a>, 2013 having its registered
office at Corporate House, Near Sola Bridge, S. G. Highway, Thaltej
Ahmedabad- 380 054 Gujarat with its manufacturing plant at Plot No.
423/P/A Sarkhej-Bavla Highway, Village Moraiya, Taluka-Sanand,
Ahmedabad -382 213 is engaged in the business of manufacturing and
marketing pharmaceutical preparations and that sometime in the third
week of December 2017, the appellant herein came across the
medicine of the defendant i.e. the respondent herein being sold at



<span class="hidden_text" id="span_4">FAO 447/2018                                                Page 4 of 87</span>
 Delhi under the impugned mark &#x27;BEVATAS&#x27;, which               on upon
enquiry was learnt to have been launched in October 2017 and the
application of the defendant i.e. the respondent herein to the present
appeal was found by the appellant herein having been published for
registration   of the impugned       trademark   &#x27;BEVATAS&#x27;       under
registration no. 3254683 dated 09.05.2016 in the trade mark journal
under no. 1768 dated 24.10.2016 and that the defendant i.e. the
respondent herein had filed the said application on &quot;proposed to be
used&quot; basis and that the appellant thus filed its notice of opposition
before the trade mark registry on 27.12.2016 and expected that the
defendant i.e. the respondent herein would not pursue its trade mark
application but it continued to do so and the defendant i.e. the
respondent herein filed its counter-statement on 28.03.2017, which
was served by the Trade Mark Registry on the Plaintiff i.e. the
appellant herein on 12.09.2017 and the appellant herein filed its
evidence in support of opposition on 08.11.2017, which opposition
proceedings are currently pending.
</p><p id="p_11">9.    The appellant further submits that the respondent&#x27;s medicine
under the impugned mark although a cancer drug contains a different
salt namely BEVACIZUMAB and is used for the treatment of
Colorectal cancer, Ovarian cancer, Cervical cancer, Lung cancer and
recurrent gliolastoma   (a type of brain tumor). Nevertheless, the
appellant submits that the wrong administration of the drug can prove
fatal. The appellant contends that the respondent&#x27;s impugned mark
&#x27;BEVATAS&#x27; is structurally, visually and phonetically similar to the
appellant&#x27;s trade mark &#x27;BEVETEX&#x27; and competing medicines are



<span class="hidden_text" id="span_5">FAO 447/2018                                              Page 5 of 87</span>
 sold in the same dosage form i.e. injections and are sold at similar
prices and that such adoption also amounts to unfair trade practice,
unfair competition and dilution and such act also amounts to
misrepresentation and misappropriation of appellant&#x27;s goodwill-in the
trade mark &#x27;BEVETEX&#x27;.
</p><p id="p_12">10.   The appellant contends that the defendant i.e. the respondent&#x27;s
trade mark &#x27;BEVATAS&#x27; is visually, structurally and as well as
phonetically similar to the appellant&#x27;s registered trade mark
&#x27;BEVETEX&#x27;. The appellant contends that the defendant i.e. the
respondent&#x27;s mark is liable to be injuncted urgently so as to protect the
public interest at large and that the consumers ought to be protected
against confusion and deception.
</p><p id="p_13">11.   Inter alia through the plaint it has been contended by the
plaintiff i.e. the appellant herein that the profits earned by the
defendant by misappropriating intellectual property rights belonging
to the plaintiff i.e. the appellant herein including the goodwill and
reputation that vest in the trademark BEVETEX is liable to be
reimbursed to the plaintiff by directing the defendant to render truthful
accounts of profits. Inter alia the plaintiff i.e. the appellant herein had
submitted through the plaint that the injury to the goodwill and
reputation of the plaintiff i.e. the appellant herein and to the members
of the purchasing public can in no way be assessed, quantified or
compensated and therefore the illegal trade activities of the defendant
i.e. the respondent herein ought to be restrained immediately by an
order of injunction.
</p><p id="p_14">12.   The appellant as plaintiff through his suit had submitted the



<span class="hidden_text" id="span_6">FAO 447/2018                                                  Page 6 of 87</span>
 comparison between competing drugs Bevetex and Bevatas as under:
</p><pre id="pre_2">  Product        Bevetex           Bevatas                  Remarks
  features

  Company        Sun Pharma        Intas

  What is the This is              Monoclonal antibody, Very          different
  product     Paclitaxel           used as anti angiogenic class of drugs with
                                                           different
                 Injection         agent to treat various indications        &amp;
                                   cancer indications      mode of action ;
                 Concentrate for
                 Nanodispersion

  Presentation   vials of 100mg    Vials 100mg &amp; 400 Almost same
                 &amp;                 mg
                 300mg

  Dosage         260 mg/m2 to 10 to 15 mg/ mg
  approved       295      mg/m2 repeated every 2 or 3
                 every 21 days. weeks.

  Route       of IV Infusion       IV Infusion              Same
  administration

  Effective dose 400 mg            700 to 900 mg (2 vials   400 mg Bevetex &amp;
  based on BSA                     or more of 400 mg        Bevetas can be
                                   used). 100 mg for        confused at the
                                   titration                pharmacy / para
                                                            medical level.

  Broadly        Metastatic        1. Metastatic            Non overlapping
  recommended    breast cancer                              indications.
  for                              colorectal
                                                           Patient may get
                                   cancer,                 wrong drug for the
                                                           given indication.
                                   2.Unresectable, locally
                                                           This may cause
                                   advanced, recurrent or
                                                           severe     /   life
                                   metastatic        non-
                                                           threatening
                                   squamous NSCLC
                                                           complications with
                                   3.Recurrent             no tumour kill
                                   glioblastoma            effect.




<span class="hidden_text" id="span_7">FAO 447/2018                                                     Page 7 of 87</span>
                                  4)Metastatic renal cell
                                 carcinoma.
                                 5)Recurrent             or
                                 metastatic        cervical
                                 cancer
                                 6)Recurrent epithelial
                                 ovarian,
                                 fallopian tube,         or
                                 primary peritoneal
                                 cancer that is:
                                 platinum-resistant
                                 or platinum-sensitive

  Most        Pain, peripheral   Gastrointestinal             Very        different
  common side neuropahy,         perforation, surgery &amp;       toxicity     profile.
  effect      neutropenia,       wound            healing     Life     threatening
              leucopenia,        complications, severe        toxicities observed
              alopecia,          &amp; fatal Hemorrhage.          with Bevacizumab.
              mucosal
              inflammation,
              asthenia,
              pyrexia, nausea,
              vomiting.




</pre><p id="p_15">and thus reiterated its contention that wrong administration of the drug
can prove fatal.
</p>
<p id="p_16">13.   The defendant i.e. the respondent to the present appeal through
its written statement contended that the alleged cause of action
claimed by the plaintiff i.e. the appellant herein that there could be
confusion leading to false administration of drug by the sale of the
respondent&#x27;s drug and it was not in public interest,- is completely
unreal, far stretched and frivolous and that the respondent&#x27;s




<span class="hidden_text" id="span_8">FAO 447/2018                                                       Page 8 of 87</span>
 BEVATAS is not an off-the-shelf drug and that the drugs of the
plaintiff i.e. the appellant herein as well as of the defendant i.e. the
respondent herein in question are not and cannot be self-administered
in as much as they are IV infusion and scheduled drugs and are
available only on prescription and to be administered to the patients
through highly specialized procedures by trained and skilled personnel
within the oncology clinics and centres under the supervision of the
Specialists Oncologists during the appropriate stage of the medical
procedure.
</p>
<p id="p_17">14.   The respondent contends that the plaintiff i.e. the appellant
herein has already admitted that BEVETEX and BEVATAS contain
totally different molecule formulations/salts and that BEVETEX is a
product of the chemical formulation PACLITAXEL, which is a
synthetic chemical compound and whereas, BEVATAS is a product
of a biosimilar BEVACIZUMAB, which is rDNA in nature.
</p>
<p id="p_18">15.   The respondent has further contended that the word BEVETEX
when read, seen and spoken as owned by the plaintiff i.e. the appellant
herein bears no similarity in any manner whatsoever with the
Defendant&#x27;s/respondent&#x27;s mark BEVATAS and that the marks are
visually, structurally and phonetically different as compared below:
</p>
<pre id="pre_3"> PLAINTIFF&#x27;S MARK                DEFENDANT&#x27;S MARK
 BEVETEX                         BEVATAS
</pre><p id="p_19"> Phonetics of the mark starts Phonetics of the mark starts
 with phonics BEVE            with phonics BEVA
 Phonetics of the mark ends Phonetics of the mark ends



<span class="hidden_text" id="span_9">FAO 447/2018                                                Page 9 of 87</span>
  with phonics TEX                with phonics TAS
 No visual similarity            No visual similarity
           BEVETEX                         BEVATAS



       BRAND NAME:                   BRAND NAME:
</p><pre id="pre_4">         BEVATAS                       BEVETEX

        Defendant&#x27;s drug               Plaintiff&#x27;s drug

 Molecule:                       Molecule:

 Bevacizumab for injection       Paclitaxel         injection
                                 concentration    for Nano
                                 dispersion.

 Type of Drug:-                  Type of Drug:-

 rDNA Drug                       Synthetic Chemical Drug

 Dosage form:                    Dosage form:

 100 mg and 400 mg for 100 mg and 300 mg for
 injection             injection

 Route of Administration:        Route of Administration:

</pre><p id="p_20"> Intra venous injection andIntra venous injection and
 need to be administered byneed to be administered by
 trained oncology nurses at a
                           trained oncology nurses at
 multi-speciality     hospital
                           a multispeciality hospital
 under     supervision of aunder super vision of a
 medical       or     surgical
                           medical     or     surgical
 oncologist.               oncologist Unlike other
                           injectable medicines it
 Unlike   other injectable
                           cannot be administered at
 medicines it cannot be



<span class="hidden_text" id="span_10">FAO 447/2018                                               Page 10 of 87</span>
  administered at any common any common hospital or
 hospital or clinic Bevatas clinic
 cannot be sold without
 prescription     of    any
 oncologist.
</p>
<pre id="pre_5"> Therapy:                        Therapay:

 For the treatment purpose       For the treatment purpose

 IMS category                    IMS category

</pre><p id="p_21"> Monoclonal antibody (Anti Cytotoxic agent or
 Vascular endothelial growth microtubule
 factor)
                             Inhibitor

 Prescribed by                   Prescribed by

 Medical /      Surgical     and Medical / Surgical and
 Radiation                       Radiation

 Oncologist                      Oncologist

 Product appearance              Product appearance

 Vial for injection in a single Vial for injection in a
 pack                           single pack

 Indication:                     Indication:
</p>
<p id="p_22"> First-line treatment of non-    After       failure     of
 squamous        NSCLC     in    combination chemotherapy
 combination with platinum-      for   Metastatic    breast
 based           chemotherapy    cancer (mBC) or relapse
 Metastatic carcinoma of the     within 6 months of
 colon or rectum (mCRC)          adjuvant chemotherapy

 Advanced and/or metastatic




<span class="hidden_text" id="span_11">FAO 447/2018                                                 Page 11 of 87</span>
  renal cell cancer (mRCC)

 Epithelial ovarian, fallopian
 tube and primary peritoneal
 cancer Cervical Cancer
 Glioblastoma       Metastatic
 breast cancer (mBC)

 Type of medicine:               Type of medicine:</p><pre id="pre_6">

 Hospital based medicine         Hospital based medicine
 need to supply against          need to supply against
 prescription of registered      prescription of registered
 medical     practitioner or     medical practitioner or
 oncologist only.                oncologist only.

 Need to administered as a       Need to administered as a
 intra venous injection by       intra venous injection by
 trained oncology nurses         trained oncology nurses
 under the supervision of        under the supervision of
 registered         medical      registered        medical
 practitioner (90 minutes        practitioner (30 minutes
 infusion)                       infusion)

 MRP                             MRP

</pre><p id="p_23"> Bevatas: Rs.39995/- for Bevetex: 100 mg: Rs.
</p><p id="p_24"> 400mg and Rs. 25990.00 12500/- 300 mg- 37000/-
</p><p id="p_25"> for 100mg.
</p>
<pre id="pre_7"> Dose:                           Dose:

 The recommended dose of         260 mg/m2 and Bevetex
 bevacizumab is 7.5 mg/kg or     295 mg/m2 every 3 weeks
 15 mg/kg of body weight         ad IV infusion over 30
 given once every 3 weeks as     minutes.
 an IV infusion in Non-small




<span class="hidden_text" id="span_12">FAO 447/2018                                             Page 12 of 87</span>
  cell lung cancer Advanced
 and/or metastatic renal cell
 cancer (mRCC) : The
 recommended      dose    of
 bevacizumab is 10 mg/kg of
 body weight given once
 every 2 weeks as an IV
 infusion.

 Epithelial ovarian, fallopian
 tube and primary peritoneal
 cancer: The recommended
 dose of bevacizumab is 15
 mg/kg of body weight given
 once every 3 weeks as an IV
 infusion.



</pre><p id="p_26">16.   The respondent further submitted that its mark is only
associated with the respondent/defendant by virtue of long, continuous
and extensive use and likelihood of confusion is nil as the drugs being
sold under the plaintiff&#x27;s and Defendant&#x27;s marks are totally different.
</p>
<p id="p_27">17.   The respondent has further submitted that there is no case of
passing off and unfair competition made out and that the mark of the
plaintiff i.e. the appellant herein came to use in the year 2015 only
despite the registration having been applied for in the year 1983 and
having been so granted in 1990 and that the defendant&#x27;s i.e. the
respondent&#x27;s mark was coined and adopted in the year 2016 and that
the defendant&#x27;s/respondent&#x27;s brand has acquired a huge reputation and
goodwill in a short span of time because of the excellent quality of the



<span class="hidden_text" id="span_13">FAO 447/2018                                                 Page 13 of 87</span>
 respondent&#x27;s drug and its demand. The respondent has further
submitted that the plaintiff i.e. the appellant herein is selling the drug
BEVETEX with active formulation called Paclitaxel which is a
chemotherapy drug used primarily for indication of early breast cancer
and that the respondent has also been selling the said active
formulation of Paclitaxel but under the brand name Cytax and that the
respondent is also marketing nanosornal Paclitaxel Lipid Suspension
under the brand name Pacliaqualip and that the standard dose of
Paclitaxel which is recommended is often 175 mg per/m2.
</p>
<p id="p_28">18.     The respondent has further submitted that its drug BEVATAS
is a monoclonal antibody which is a biologic drug derived from
mammalian clone cells and are biologic drugs and precisely not the
chemical drugs and that BEVATAS               which is a monoclonal
antibodies are derived from mammalian clone (Human Umbilical
Vascular Endothelial Cells C - HUVEC Cells) which through various
biological processes disintegrates and forms proteins as opposed to
traditional cytotoxic which are formulated by combining two or more
chemical entities and that BEVATAS is a monoclonal antibody, an
anti-Vascular Endothelial Growth Factor targets the Vascular
Endothelial Growth Receptor and inhibits and reduces the
proliferation (multiplication / growth) of tumour cells in various
indications like:
</p>
<blockquote id="blockquote_1">      a. Metastatic Carcinoma of the Colon or Rectum, say a disorder
        associated with digestive system;
</blockquote>



<span class="hidden_text" id="span_14">FAO 447/2018                                                 Page 14 of 87</span>
<blockquote id="blockquote_2">       b. Advanced Epithelial Ovarian, Fallopian Tube and Primary
         Peritoneal cancer, say a disorder associated with reproductive
         system in female population;
</blockquote><blockquote id="blockquote_3">      c. Persistent, recurrent or metastatic carcinoma of the Cervix, say
         a disorder associated with reproductive system in female
         population;
</blockquote><blockquote id="blockquote_4">      d. Unresectable advanced, metastatic or recurrent Non-small Cell
         Lung cancer, say a disorder associated with lungs;
      e. Advanced and. / or metastatic Renal Cell cancer, say a disorder
         associated with kidneys;
</blockquote><blockquote id="blockquote_5">      f. Recurrent Glioblastoma with progressive disease, say a disorder
         associated with brain; and
      g. Metastatic breast cancer, say a disorder associated with breast.
</blockquote>

<p id="p_29">19.      Inter alia the respondent has submitted that permission for
marketing and manufacturing the said rDNA drug i.e. BEVATAS was
granted by the Drug Controller General of India (DCGI), Directorate
General of Health Services on 23.06.2016 and 27.06.2016 and by the
Deputy Commissioner, Food &amp; Drugs Control Administration,
Gujarat State, Gandhinagar on 30.07.2016. Inter alia the respondent
has submitted that its product had been immensely used and
prescribed by the medical practitioners since its launch and that the
plaintiff always knew that the respondent&#x27;s product was in the market
and, therefore, the present suit suffers from delay, latches and
acquiescence.
</p>



<span class="hidden_text" id="span_15">FAO 447/2018                                                  Page 15 of 87</span>
<p id="p_30"> 20.      Inter alia the respondent has submitted that BEVATAS can
only      be   supplied   against    the     demand   from   the    cancer
hospitals/institutions and that too against the prescription of a cancer
specialist and cannot be purchased. Inter alia the respondent has
submitted that administration of both the products is by or under the
close supervision of super speciality medical professionals like
medical and surgical oncologists. Inter alia the respondent has
contended that administration of both the products is through IV
infusion in oncology centre / clinic having lengthy and specialized
procedures which involve:
</p><blockquote id="blockquote_6">      a. pre-screening of patients and assessment of vital parameters like
         blood count;
</blockquote><blockquote id="blockquote_7">      b. pre-medication for prevention of nausea and vomiting;
      c. preparation of the recommended dosage and infusion within
         specialized earmarked wards;
</blockquote><blockquote id="blockquote_8">      d. actual process of infusion takes around 90 minutes for
         BEVATAS which under the constant monitoring of highly
         trained and skilled medical professionals;
      e. because of peculiar nature and usage of Onco range of products,
         these are completely hospital based and are supplied against the
         prescription of medical oncologist which is being administered
         within the Onco clinic or centre.
</blockquote><p id="p_31">21.      The respondent has submitted that the whole process of infusion
is a half or full day programme for the patient depending upon its
medical condition before and after infusion. The respondent has
further submitted that it is not possible that a specialist doctor gets



<span class="hidden_text" id="span_16">FAO 447/2018                                                 Page 16 of 87</span>
 confused by the two different drugs with different trade marks as the
super-specialists have complete information/knowledge and are aware
of the differences. The respondent has put forth the comparison and
the different in administration of the two products as under:
</p><pre id="pre_8">   PARTICULARS BEVACIZUMAB                      PACLITAXEL
                       (BEVATAS)                (BEVETEX)
   Reconstitution      It should be diluted     It should be diluted
                       with 0.9% sodium         with     5%      w/v
                       chloride solution for    dextrose injection
                       injection.        The    in 1:20 ratio. Each
                       concentration of the     ml of reconstituted
                       final    Bevacizumab     Nanodispersion
                       solution should be       contains    5   mg
                       kept within the range    paclitaxel    (Drug
                       of 1.4 to 16.5 mg/ml.    concentration will
                                                be 5 mg/ml.)
   Administration      The      initial  dose   It has to           be
                       should be delivered      administered        as
                       over 90 minutes as       intravenous
                       an IV infusion. If the   infusion over      30
                       first infusion is well   minutes every       3
                       tolerated, the second    weeks.
                       infusion may be
                       administered over 60
                       minutes. If the 60-
                       minute infusion is
                       well
                       tolerated,        all
                       subsequent infusions
                       may be administered
                       over 30 minutes.
                       Bevacizumab



<span class="hidden_text" id="span_17">FAO 447/2018                                                Page 17 of 87</span>
                          infusion    frequency
                         varies from 2
                         weekly to 3 weekly
                         depending on the
                         indication.


</pre><p id="p_32">22.      The respondent reiterates that as the medicines cannot be sold
by any medical practitioner, there is no scope for confusion of any
kind. The respondent has further submitted that its trade mark Bevatas
is totally different from the plaintiff&#x27;s trademark Bevetex and the
respondent&#x27;s mark is coined mark which has been coined by
amalgamating the words BEVA derived from or referable to the active
ingredient BEVACIZUMAB and TAS from Defendant&#x27;s Corporate
name INTAS, a company of a repute and standing since the last
several decades. The respondent has further submitted that within the
product range BEVACIZUMAB, a number of companies are using
prefix &#x27;BEVA&#x27; in the trademark for their respective products such as
BEVATAS (of the Defendant/respondent), BEVACIREL (Reliance),
BEVAZZA (Lupin) and BEVAREST (Emcure). The respondent has
put forth an illustrative chart to show the respective users of product
range of BEVACIZUMAB which is as follows:
</p><p id="p_33">                           PRE- PLAINTIFF
   S.NO.       APPLICATION PARTCULARS MARK
</p><p id="p_34">   01.         No.- 340724                       BEVARATE
               Application Date- 12.09.1978
               Registration Date - 07.07.1980




<span class="hidden_text" id="span_18">FAO 447/2018                                               Page 18 of 87</span>
</p><p id="p_35">    02.         No.- 373052                        BEVISAR
               Application Date- 05.03.1981
               Registration Date - 23.04.1966


                         POST- PLAINTIFF
   S.NO.         APPLICATION                      MARK
                 PARTCULARS
</p><p id="p_36">   01.           Application No.- 827384          BEVAC
                 Application Date- 13.11.l998
                 Registration Date - 09.06.2017
</p><p id="p_37">   02.           Application No.- 451957          BEVIN
                 Application Date- 02.04.1986
                 Registration Date - 14.08.1991
</p><p id="p_38">   03.           Application No.-713912           BEVENT
                 Application Date- 13.08.1996
                 Registration Date - 01.12.2003
</p><p id="p_39">   04.           Application No.- 792186          BEVIZ
                 Application Date- 20.02.1998
                 Registration Date - 31.03.2005
</p><p id="p_40">   05.           Application No.- 890171          BEVAC- A
                 Application Date- 07.12.1999
                 Registration Date - 28.02.2005
</p><p id="p_41">   06.           Application No.- 902979          BEVITAL
                 Application Date- 11.02.2000




<span class="hidden_text" id="span_19">FAO 447/2018                                              Page 19 of 87</span>
                Registration Date - 22.04.2005
</p><p id="p_42">   07.         Application No.- 927555          BEVAXIM
               Application Date- 26.05.2000
               Registration Date - 01.08.2006
</p><p id="p_43">   08.         Application No.- 1169016         BEVAL
               Application Date- 24.01.2003
               Registration Date - 23.03.2006
</p><p id="p_44">   09.         Application No.- 1195752         BEVON
               Application Date- 01.05.2003
               Registration Date - 29.10.2005
</p><p id="p_45">   10.         Application No.- 1450700         BEVATRON
               Application Date- 05.05.2006
               Registration Date - 11.03.2010
</p><p id="p_46">   11.         Application No.- 1695478         BEVAMAB
               Application Date- 05.06.2008
               Registration Date - 04.11.2009
</p><p id="p_47">   12.         Application No. - 1912248        BEVACEPT
               Application Date- 22.01.2010
               Registration Date - 28.03.2011
</p><p id="p_48">   13.         Application No.- 2453934         BEVACIREL
               Application Date- 03.01.2013
               Registration Date - 07.04.2017
</p><p id="p_49">   14.         Application No.- 3190977         BEVAZZA




<span class="hidden_text" id="span_20">FAO 447/2018                                            Page 20 of 87</span>
                 Application Date- 22.02.2016
                Registration Date - 23.02.2017
</p><p id="p_50">      15.       Application No.- 1329340          BEVEL
                Application Date- 31.12.2004
                Registration Date - 04.06.2007
</p><p id="p_51">      16.       Application No.- 2811849          BEVESPI
                Application Date- 18.09.2014
                Registration Date - 25.11.2016


</p><p id="p_52">23.     The respondent has further submitted that its product has the
suffix &#x27;TAS&#x27; which is referable and derived from the respondent&#x27;s
corporate name and house mark &quot;INTAS&#x27;, so as to indicate that the
product is emanating or otherwise belonging to the respondent, a
globally reputed pharmaceutical company and that it is a very
common practice, especially in the pharmaceutical industry to adopt /
conceive trademark by amalgamating the name of the molecule / salt
with the name of the manufacturing / marketing company and that
there are a large number of products in its basket which have the
trademarks with the suffix &#x27;TAS&#x27; by amalgamating with the name of
the molecule / active ingredient or salt which are already registered in
the name of the respondent in Class 5 as the respondent always has an
inclination to coin a Trademark by adopting TAS as a suffix so as to
indicate association of the product to its Corporate name. The
respondent has put up an illustrative list of such registered trademarks
as detailed as under:
</p>



<span class="hidden_text" id="span_21">FAO 447/2018                                               Page 21 of 87</span>
<pre id="pre_9">           S.No.   APPLICATION NO.       MARK
         01.      629454            LOMITAS
         02.      727061            SPARTAS
         03.      748044            CLARITAS
         04.      750610            RUMENTAS
         05.      761079            LOSARTAS
         06.      761125            CEFITAS
         07.      802659            AMTAS
         08.      809669            SERTAS
         09.      851467            ALBUTAS
         10.      859149            OFOTAS
         11.      859152            OFLOTAS
         12.      877077            SPRINTAS
         13.      935241            FENTAS
         14.      983667            TINITAS
         15.      989312            FLUTAS
         16.      1076825           FERITAS
         17.      1172229           MINOTAS
         18.      1191911           SOLVITAS
         19.      1191914           NORTAS
         20.      1261518           SALBITAS
         21.      1285442           DORTAS
         22.      1292795           LIPYTAS




<span class="hidden_text" id="span_22">FAO 447/2018                                   Page 22 of 87</span>
          23.       1293256                  GFLOTAS
         24.       1334640                  CARVEDTIAS
         25.       1334641                  LISINOTAS
         26.       1368921                  ECOTAS
         27.       1399376                  LEVOTAS
         28.       1399381                  ERYTAS
         29.       1421630                  LOPATAS
         30.       1601636                  DOXYTAS
         31.       1621395                  SOFTAS
         32.       1662898                  NIFTAS
         33.       1773262                  DERITAS
         34.       1777086                  ZOLITAS
         35.       1891289                  CLINTAS
         36.       1898125                  OVUTAS
         37.       1898127                  LUPROTAS
         38.       1902866                  ENZYTAS
         39.       1988968                  LIQUITAS
         40        2014042                  ARGITAS


</pre><p id="p_53">24.   The respondent has further submitted that the Trademark
Examiner whilst examining the trademark application of the defendant
i.e. the respondent herein, did not cite the mark of the plaintiff i.e. the
appellant herein as a conflicting mark which shows beyond doubt that
there is no similarity in any manner whatsoever between the




<span class="hidden_text" id="span_23">FAO 447/2018                                                  Page 23 of 87</span>
 respondent&#x27;s and the appellant&#x27;s marks as alleged. The respondent
thus contends that all parameters like nature of the product, its
characteristics, indications for which they are used, unique logo of
depicting Bevatas is in two different colours for differentiating BEVA
and TAS with the product pack containing lettering style prominently
displayed with its Intas logo in an artistic presentation.
</p><p id="p_54">25.   The respondent further submits that its mark is a coined mark
coined by the combination of prefix &#x27;BEVA&#x27; from the active ingredient
of the drug i,e. BEVCIZUMAB and &#x27;TAS&#x27; is from the suffix from the
name of the defendant/respondent i.e. INTAS, in accordance with
common prevalent practice in the pharmaceutical industry and that the
mark of the respondent has nothing to do with the trademark of the
appellant and there is no similarity or resemblance with it neither
structural nor phonetic and no case of infringement is made out and
that the defendant/respondent&#x27;s mark is its own independent
intellectual property capable of distinguishing the product of the
respondent from the world at large including those of the appellant.
</p><p id="p_55">26.   The respondent has further submitted that it is a well settled
principle of law that no one can claim a monopoly in respect of a
particular International Non-Proprietary Name (INN name) of the drug
and that Bevacizumab is the INN name of the drug being sold by the
Defendant under the mark Bevatas.
</p><p id="p_56">27.   The plaintiff i.e. the appellant herein has stated that the suit has
been filed purely in public interest and that the plaintiff i.e. the
appellant herein has no commercial interest but submits that if a
wrong drug is administered, the same may cause Gastro Intestine



<span class="hidden_text" id="span_24">FAO 447/2018                                                 Page 24 of 87</span>
 Perforation i.e. creating holes in the stomach which would eventually
prove fatal.
</p><p id="p_57">28.    The learned trial Court vide its impugned order observed to the
effect that:
</p><p id="p_58">  &quot;Findings:-
</p><p id="p_59">  &quot;I have heard the rival submissions made by the Ld. Counsel for
  parties and also carefully gone through the written submission
  and supporting case laws placed on record by both the parties.
  In my considered opinion the application filed by the plaintiff
  u/O 39 R 1 and 2 CPC needs to be dismissed for the reasons
  stated here under:-
</p><p id="p_60">  6.1 Worth to mention at the outset that both the sides have cited
  plethora of case law in support of their submissions, it is stated
  that there is no dispute to the proposition of law enunciated
  therein, the determining principles remains the same, the
  outcome depends upon the particular facts and circumstances of
  each case.
</p><p id="p_61">  6.2. The entire controversy herein is centered around whether
  the defendant&#x27;s trademark &#x27;BEVATAS&#x27; is deceptively similar to
  that of the plaintiff&#x27;s trademark &#x27;BEVETEX&#x27;. Plaintiff&#x27;s mark is
  registered whereas defendant&#x27;s mark is under objection before
  the registrar Trademark. There is no doubt that registration of
  trademark gives the registered proprietor thereof exclusive right
  to use of the trademark in relation to the goods or services in
  respect of infringement of the trademark as stipulated in Sec-
  28(1) Trademark Act.
</p><p id="p_62">  6.3 <a href="/doc/667743/" id="a_3">Section 28(1)</a> of the Act confers upon the registered
  proprietor of a trademark, the exclusive right, upon a valid
  registration, to the use of the trademark in relation to goods or
  services in respect of which the trademark is registered. <a href="/doc/1377106/" id="a_4">Section
  29(1)</a> provides that a registered trade mark is infringed by a
  person who, not being a registered proprietor or a person using



<span class="hidden_text" id="span_25">FAO 447/2018                                               Page 25 of 87</span>
   by way of permitted use, uses in the course of trade, a mark
  which is identical with, or deceptively similar to the trade mark
  in relation to goods or services in respect of which the trade
  mark is registered and in such manner as to render the use of the
  mark likely to be taken as being used as a trade mark.
  6.4 The expression &quot;deceptively similar&quot; is defined in <a href="/doc/117176/" id="a_5">Section
  2(l)(h)</a>- &quot;A mark shall be deemed to be deceptively similar to
  another mark if it so nearly resembles that other mark as to be
  likely to deceive or cause confusion.&quot;
</p><p id="p_63">  6.5. In factual matrix of the case, it is apparent that the trade
  mark used by the defendant &quot;BEVETAS&quot; is not a registered
  trademark. It is also apparent that the defendant&#x27;s mark
  &quot;BEVETAS&quot; is not per se identical with the plaintiffs registered
  mark &quot;BEVETEX&quot;. Noticeably the defendants and plaintiff
  trademark are not in relation to the same molecule/product/salt.
  Therefore, the only question that has to be examined whether the
  defendant&#x27;s mark is deceptively similar/ confusingly similar to
  the plaintiffs registered trademarks thereby entitling to the
  interdiction against the defendant to its use.
  6.6. It is not uncommon, rather, I would say in pharmaceutical
  trade it is a normal practice to have prefixes or suffixes linked to
  chemical salt or compound across various similar products
  manufactured by different companies. It is also common to have
  the abbreviated name of the company in conjunction with such
  prefix or suffix of the salt to indicate the source of the product.
  6.7 In view of the pharmaceutical trade, one finds name of
  various drugs almost similar to each other, having common
  prefixes of suffixes, for the reason that the name of the drug
  conveys as to which salt/ compound it is a derivative of drug.
  Acronyms and short forms are commonly used as a trademark.
  6.8 Meaning thereby, having prefix or suffix conjunctively with
  company name is the normal practice in pharmaceutical
  business. And trite to say that to judge the similarity the two




<span class="hidden_text" id="span_26">FAO 447/2018                                                Page 26 of 87</span>
   marks are to be compared as a whole, it is not legally
  permissible to dissect it to minutely compare the marks with
  microscopic eye. What it means in the context of the present case
  is that in the pharmaceutical trade it would not be unusual to
  find drugs including the term &#x27;BEVE&#x27; as a prefix in plaintiffs
  mark and &#x27;BEVA&#x27; in defendant&#x27;s mark. And significantly, the
  chemical compound &#x27;Bevacizumab&#x27; in the defendant&#x27;s drug is
  totally different from the compound/salt of plaintiff drug, i.e.
  &#x27;Paclitaxel&#x27;.
</p><p id="p_64">  6.9 With above noted factors in mind I proceed to examine
  whether the two marks in question are deceptively/confusingly
  similar or not.
</p><p id="p_65">       To the said word &#x27;BEVE&#x27;, plaintiff has added suffix &#x27;TEX&#x27; to
  arrive at the trademark &#x27;BEVETEX&#x27;. On the other hand, the
  defendant has added the suffix &quot;TAS&quot;, which is part of its
  company name (INTAS), to arrive at the trademark &#x27;BEVATAS&#x27;.
  The trademarks in this case, be it the plaintiffs&#x27; registered
  trademark or the defendant&#x27;s trademark are what is described as
  hybrid or blended words.
</p><p id="p_66">  6.10. In the facts of the case, it would be fruitful to refer to the
  decision of the Ho&#x27;ble High Court of Delhi reported as
  <a href="/doc/1509899/" id="a_6">Astrazeneca UK Ltd. V. Orchid Chemicals and
  Pharmaceuticals Ltd</a>. : 2007(34) PTC 469 (Del) wherein
  similar words in competing marks being public jurisdiction was
  considered and it was held as under:
</p><blockquote id="blockquote_9">       &quot;21. In our considered opinion the facts of the said case
       are almost similar and squarely applicable to the facts
       of the present case. &#x27;Meropenem&#x27; I the moleculte which
       is used for treatment of bacterial infections. In that view
       of the matter, the abbreviation &#x27;Mero&#x27; became a generic
       term, is publici jurisdiction and it is distinctive in
       nature. Consequently, the appellants/plaintiffs cannot
       claim exclusive right to the use of &#x27;Mero&#x27; as constituent




<span class="hidden_text" id="span_27">FAO 447/2018                                                Page 27 of 87</span>
       of any trademark. The possibility of deception or
      confusion is also reduced practically to nil in view of
      the fact that the medicine is sold only on prescription by
      dealers. The common feature in both the competing
      marks i.e. &#x27;Mero&#x27; is only descriptive and publici
      jurisdiction and, therefore, the customers would tend to
      ignore the common feature and would pay more
      attention to the uncommon feature. Even if they are
      expressed as a whole, the two did not have any phonetic
      similarity to make it objectionable. There are at least
      four other registered users of the prefix &#x27;Mero&#x27; in India
      whereas the names of 35 companies using &#x27;Mero&#x27;
      trademarks, which have been registered or applied for
      registration, have been furnished in the pleadings. The
      respondent/defendant       advertised    its   trademark
      &#x27;Meromer&#x27; after submitting its applicant for registration
      and at that stage, there was no opposition even from the
      appellants/plaintiffs.    The     trademark      of    the
      respondent/defendant was registered there being no
      opposition from any quarter, including the
      appellants/plaintiffs&quot;
</blockquote>
<p id="p_67">  6.11 For the plaintiff to succeed, it must also be established that
  the defendant has no right to use the genuine
  name/abbreviations of the compound &#x27;Bevacizumab&#x27; in their
  drugs, and that the plaintiff has exclusive right to use the same
  and which the plaintiff has failed to show.
</p><p id="p_68">  6.12. Thus, it is clear that parts of words can be combed to pack
  the meanings of both the words in the new word so formed. And
  the defendant has been able to show the derivation of the
  trademark &#x27;BEVATAS&#x27;. &#x27;BEVA&#x27; from &#x27;Bevacizumab&#x27; and &#x27;TAS&#x27;
  from its name/trade name &#x27;INTAS&#x27; which apparently is also
  reflected from other prominent brands of the defendant being




<span class="hidden_text" id="span_28">FAO 447/2018                                               Page 28 of 87</span>
   continuously used since long. Necessary documents to support
  the said view have been placed on record by the defendant.
  6.13. Further, in my view the defendant&#x27;s trademark has been
  derived by combining the publici- juris, the abbreviation of the
  salt &#x27;Bevacizumab&#x27; with suffix TAS, the abbreviated form of its
  trade/company name.
</p><p id="p_69">  6.14. Defendant has also placed on record a list of third party
  use of Similar trademark with abbreviated prefix &#x27;BEVA&#x27; to their
  merchandise/drugs as detailed in paras 18 and 30 of the WS. To
  name a few BEVATAS (of the defendant), BEVACIREL
  (Reliance), BEVAZZA (Lupin), Bevarest (Emcure), AVASTIN
  (Roche) and ZYBEV (Zydex U.S.) And relevant to note the list
  includes prominent names in pharmaceutical industry.
  6.15. Defendant has also placed on record large number of
  products which have the trademarks with the suffix &#x27;TAS&#x27; by
  amalgamating with the name of molecule/active ingredient or
  salt which are already registered in the name of the defendant in
  class 5. And apparently substantive use by the defendant of the
  mark for its products is also demonstrated by placing on record
  invoices/bills etc.
  6.16. We must not lose sight of the fact that herein we are at
  preliminary stage therefore the validity, relevancy and
  weightage of the documents placed on record can be tested
  during course of trial, at this stage, prima-facie opinion in
  favour of defendant is supported by these documents. And
  thereafter in my view, plaintiff can not have any monopoly over
  the use of the word &#x27;BEVA&#x27;. The Prefix &#x27;BEVA&#x27; is derived from
  &#x27;Bevacizumab&#x27; which conveys as to which salt it is derivative of.
</p><p id="p_70">  7. Now coming to factual aspect of similarity or deceptive
  similarity -
</p><p id="p_71">  7.1. Ocular/ Visual similarity:-it is important to note that there is
  markedly difference between the two trademarks in dispute here.
  Plaintiffs mark comprised of &#x27;BEVETEX&#x27; whereas the mark of




<span class="hidden_text" id="span_29">FAO 447/2018                                                 Page 29 of 87</span>
   the defendant &#x27;BEVATAS&#x27; is depicted along with the name of
  the salt in small font underneath. Both the trademarks are
  prominently qualified by the name of the compound which ex-
  facie is completely different, i.e. Paclitaxel and Bevacizumab.
  And important to note that the name of the salts are
  predominantly reflected overshadowing the trademarks on the
  packaging. The get-up, the trade-dress of the two products is
  different making it highly unlikely of any confusion amongst its
  consumers. And taking note of above discussion and the font
  thereof I can thoughtfully say that there is no structural
  similarity also.
</p><p id="p_72">  7.2. Phonetically also, I find apparently there is no similarity in
  the two words. The word &#x27;Bevetex&quot;  &amp;   and &#x27;Bevetas 
  &amp;  (Hindi varaamala uchcharan) and pronounced as a
  whole they do not rhyme with each other.
</p><p id="p_73">  8. Thus, it cannot lead to the conclusion that any slight
  semblance of phonetic similarity between two marks would
  automatically satisfy the test of confusion to a man as a whole.
  In entirety of the facts, looking at the two marks as a whole, I do
  not see any likely hood of confusion or deception and/or
  similarity     between      the    two     marks    amongst     the
  customers/consumers. The two marks are entirely different and
  distinct. There is no phonetically or visual similarity between the
  two mark taken as a whole.
</p><p id="p_74">  9. Further both the drugs are schedule H, IV Injunction Drugs
  and cannot be self administered. Nor it can be said that they are
  &#x27;Over The Counter&#x27; drugs or for that matter easily/readily
  available on self medication, a general tendency within our
  society.
</p><p id="p_75">  10. Drugs are available only on prescriptions and can be
  administered to the patients by highly specialized -super
  specialist oncologists and under their supervision though
  specialized producers by trained &amp; Skilled personnel within




<span class="hidden_text" id="span_30">FAO 447/2018                                               Page 30 of 87</span>
   oncology centers. Both the drugs are sold under different
  contents/weight and the price , i.e.
</p><p id="p_76">      (i) BEVATAS- 400 mg cost: Rs. 39,995/- 100 mg cost: Rs.
  25,990/-
</p><p id="p_77">      (ii) BEVETEX- 300 mg cost: Rs. 37,000/- -100 mg cost: Rs.
  32,500/-.
</p>
<p id="p_78">  11. Herein another import factor that needs to be considered
  and in my view very relevant to the facts of the case is who are
  the customers /targeted users, the persons who are likely to
  purchase the drugs in question here. And I must state that it is
  not the general public or unwary customer in the bracket of
  targeted customers/ consumers. The customer of the two
  products are not illiterate persons or a common man. But highly
  specialized doctors and equally talented and specialized medical
  staff where the chance of confusion are practically negligible.
</p><p id="p_79">  12. At this juncture a useful reference may be made to the para
  42 of the <a href="/doc/1114158/" id="a_7">Cadila Healthcare v. Cadila Pharmaceuticals</a> AIR
  2001 SC 1952 read as under:-
</p><blockquote id="blockquote_10">        &quot;42. Broadly stated in an action for passing off on the
        basis of unregistered trade mark generally for deciding
        the question of deceptive similarity the following
        factors to be considered:
</blockquote><blockquote id="blockquote_11">        a) The nature of the marks i.e. whether the marks are
        word marks or label marks or composite marks, i.e.
        both words and label works.
</blockquote><blockquote id="blockquote_12">        b) The degree of resembleness between the marks,
        phonetically similar and hence similar in idea.
</blockquote><blockquote id="blockquote_13">        c) The nature of the goods in respect of which they are
        used as trade marks.
</blockquote><blockquote id="blockquote_14">        d) The similarity in the nature, character and
        performance of the goods of the rival traders.
</blockquote>



<span class="hidden_text" id="span_31">FAO 447/2018                                             Page 31 of 87</span>
<blockquote id="blockquote_15">         e) The class of purchasers who are likely to buy the
        goods bearing the marks they require, on their
        education and intelligence and a degree of care they
        are likely to exercise in purchasing and/or usin2 the
        goods.
</blockquote><blockquote id="blockquote_16">        f) The mode of purchasing the goods or placing orders
        for the goods and g) Any other surrounding
        circumstances which may be relevant in the extent of
        dissimilarity between the competing marks.
</blockquote><blockquote id="blockquote_17">                                       (emphasis supplied).&quot;
</blockquote>
<p id="p_80">  13. All the circumstances such as nature of products, their
  indications, being intravenous products self-administration is
  not possible and the entire process is done under the constant
  monitoring, guidance and supervision of super specialists, one
  product being mistaken for other or is replaced by the other is
  completely ruled out. It is impossible that a super specialist
  doctor gets confused in as much as both the trademarks are
  completely different and are being used for completely different
  drugs and indications of which super specialist doctors have
  complete information, knowledge and are aware of.
</p><p id="p_81">  14. Analyzing the facts in backdrop of above discussion it
  becomes highly unlikely that there can be any deception or
  confusion or chance of wrong administrations of the drugs.
  Aberrations are always there. That too cannot apparently be due
  to confusion/deception qua the drugs but attributable so to
  gross-negligence or carelessness of the person.
</p><p id="p_82">  15. Significant to note that plaintiff had applied for registrations
  of the mark BEVETEX in the year 1983 which was granted in
  1990. Merely because plaintiff got its mark registered in 1990
  vide its application filed in year 1983 would not by itself give
  any right in the said trademark when admittedly it was not




<span class="hidden_text" id="span_32">FAO 447/2018                                                Page 32 of 87</span>
   commercially used for newly 2 decades. &#x27;Hoading&#x27; and &#x27;Parking&#x27;
  of trademark cannot permitted and encouraged.
</p><p id="p_83">  16. Besides that as discussed above in the preceding paras that
</p><p id="p_84">  (a) noticeably there is no deception or confusion of the two
  trademarks in question,
</p><p id="p_85">  (b) &#x27;beve&#x27; is not abbreviated form of the salt Paclitaxel and
  plaintiff cannot have monopoly over in light of established trade
  practice,
</p><p id="p_86">  (c) there is no similarity between the marks; The two marks are
  distinct and dissimilar; visually / phonetically.
</p><p id="p_87">  (d) No misrepresentation or mala fides can be attributed to the
  defendants, &#x27;TAS&#x27; is part of its products, commonly used
</p><p id="p_88">  (e) Both the products were launched seemingly within a span of
  one year and it cannot be a matter of touch and go to claim prior
  user. To claim reputation and goodwill qua the trademark
  BEVETEX in a short span of time would require evidence which
  can only be adjudicated during course of the trial. Apparently as
  of now no clear cut case of goodwill and reputation is made out
  qua the said trademark.
</p><p id="p_89">  17. The turnover of defendant&#x27;s product BEVATAS till date is
  said to be the tune of Rs. 3.5 crore/month, sales figure of Rs. 21
  crores from September 2016 till November 2017 are alleged to
  be much more than that of the plaintiff. It cannot thereby be said
  that defendant is trying to encash upon the reputation and good
  will of the plaintiffs trademark.
</p><p id="p_90">  18. Essential ingredients of the passing off not made out in
  favour of the plaintiff. Therefore, at this stage, it cannot be said
  that the plaintiff has made out a prima facie case for grant of
  interim protection under the doctrine of passing off.
</p><p id="p_91">  19. With respect to the authorities relied upon by the plaintiff
  suffice to state that none of the authority in there was dealing
  with the scheduled H drug life saving drugs, administered
  through a complex and detailed procedure and that too by highly




<span class="hidden_text" id="span_33">FAO 447/2018                                                Page 33 of 87</span>
   specialized persons by highly specialized procedure within the
  oncology clinic and centres. In so far reliance on Cadila (supra)
  is concerned, the same is misplaced. Needless to say the
  judgment is to be read in entirety and not to cull out a passage
  therefrom, in abstract, devoid of its substance and flavor.
</p><p id="p_92">  20. In view of my above discussion, I am of the view plaintiff has
  failed to established a prima facie case in its favour.
</p><p id="p_93">  21. As discussed above, both the products were launched
  seemingly within a span of one year and there is nothing on the
  record to indicate that the plaintiffs trademark has attained the
  reputation and goodwill so as to fall in the category of well
  known trademark. Moreover, the drugs in question herein are
  life saving drug essential for treatment of cancer. Thereby in
  totality of the facts it also can not be the case of balance of
  convenience in favour of the plaintiff. No irreparable injury is
  likely to be caused to the plaintiff by the use of the impugned
  mark by the defendant.
</p><p id="p_94">  22. Accordingly, Application u/0 39 R 1 &amp; 2 is dismissed.
  Nothing stated herein shall tantamount to expression on the
  merits of the case.&quot;
</p>
<p id="p_95">29.   The appellant through the present appeal submits that the
observations of the learned trial Court whereby it is speculated that
there shall be no confusion between the competing drugs, is based
on a wrong premise, that the customer of the two medicinal
products are not illiterate persons or common men but specialized
doctors and their staff and that the learned trial Court wrongly
decided the matter as if the competing drugs were Schedule &quot;L&quot;
drug, which are only dispensed to hospitals whereas the competing
drugs in question are Schedule &quot;H&quot; drugs, which are dispensed
against prescription. As regards this submission of the appellant, it



<span class="hidden_text" id="span_34">FAO 447/2018                                                Page 34 of 87</span>
 is essential to observe as already adverted to hereinabove that the
impugned order, findings of which have been reproduced in para -
9, depicts that the drugs are schedule H, IV Injunction Drugs and
can not be self administered and they are not &#x27;Over the counter&#x27;
drugs and thus are not easily, readily available for self medication.
</p><p id="p_96">30.      Inter alia the appellant contends that the impugned order is
against the law laid down by the Hon&#x27;ble Supreme Court in <a href="/doc/1114158/" id="a_8">Cadila
Healthcare vs. Cadila Pharmaceuticals</a>; AIR 2001 SC 1952 which
lays down to the effect that:
</p><blockquote id="blockquote_18">        &quot;(1) the courts may not speculate as to whether there is a
        probability of confusion
        between similar names;
</blockquote><blockquote id="blockquote_19">        (2) Public interest would support lesser degree of proof
        showing confusing similarity in the case of trade mark in
        respect of medicinal product as against other nonmedicinal
        products. Drugs are poisons, not sweets. Confusion between
        medicinal products may, therefore, be life threatening, not
        merely inconvenient;
</blockquote><blockquote id="blockquote_20">        (3) drugs sold under prescription but this fact alone is not
        sufficient to prevent confusion which is otherwise likely to
        occur; and
        (4) confusion is not uncommon among doctors and
        paramedical staff apart from the pharmacists and their staff
        dispending the medicine.&quot;
</blockquote>
<p id="p_97">and reliance was placed specifically on behalf of the appellant on
observations in para-34, 35 &amp; 39 of the said verdict to the effect that:
</p><blockquote id="blockquote_21">      &quot;34. As far as present case is concerned, although both the
      drugs are sold under prescription but this fact alone is not
      sufficient to prevent confusion which is otherwise likely to




<span class="hidden_text" id="span_35">FAO 447/2018                                                 Page 35 of 87</span>
           occur. In view of the varying infrastructure for supervision
      of physicians and pharmacists of medical profession in our
      country due to linguistic, urban, semi-urban and rural divide
      across the country and with high degree of possibility of even
      accidental negligence, strict measures to prevent any
      confusion arising from similarity of marks among medicines
      are required to be taken.
</blockquote><blockquote id="blockquote_22">      35. ...In the field of medicinal remedies, the courts may not
      speculate as to whether there is a probability of confusion
      between similar names. If there is any possibility of such
      confusion in the case of medicines public policy requires that
      the use of the confusingly similar name be enjoined.
</blockquote><blockquote id="blockquote_23">      39. Public interest would support lesser degree of proof
      showing confusing similarity in the case of trade mark in
      respect of medicinal product as against other non-medicinal
      products. Drugs are poisons, not sweets. Confusion between
      medicinal products may, therefore, be life threatening, not
      merely inconvenient Noting the frailty of human nature and the
      pressures placed by society on doctors, there should be as
      many clear indicators as possible to distinguish two medicinal
      products from each other. It is not uncommon that in hospitals,
      drugs can be requested verbally and/or under
      critical/pressure situations. Many patients may be elderly,
      infirm or illiterate. They may not be in a position to
      differentiate between the medicine prescribed and bought
      which is ultimately handed over to them.. &quot;
</blockquote>

<p id="p_98">31.      The appellant also placed reliance on the verdict in Midas
Hygiene Industries P. Ltd. and Ors. Vs. Sudhir Bhatia and Ors.
2004 (28) PTC 121 (SC) with specific reference to para-5 thereof
which reads to the effect that:
</p>



<span class="hidden_text" id="span_36">FAO 447/2018                                                  Page 36 of 87</span>
<blockquote id="blockquote_24">     &quot;5. The law on the subject is well settled. In cases of
    infringement either of Trade Mark or of Copyright normally
    an injunction must follow. Mere delay in bringing action is not
    sufficient to defeat grant of injunction in such cases. The grant
    of injunction also becomes necessary if it prima facie appears
    that the adoption of the Mark was itself dishonest.&quot;
</blockquote>
<p id="p_99">to contend that the appellant is a registered proprietor of BEVETEX
since the year 1983 and the application for registration of BEVETAS
was filed in the year 2016 on proposed to be used basis, which stands
opposed by the plaintiff i.e. the appellant herein before the Trade
Mark Office. The appellant also contends that reliance placed by the
learned trial Court on the judgment in <a href="/doc/1509899/" id="a_9">Astrazeneca UK Ltd. vs. Orchid
Chemicals</a>; (2007) ILR 1 Delhi 874 (DB) was misplaced submitting
to the effect that in the said case, the High Court was dealing with
drugs MEROMER and MERONEM both of which were for the same
ailment and containing the same salt Meropenem and the Prefix
&quot;MERO&quot; was taken from the salt which was proved to have become
common to trade. Inter alia the appellant has submitted that the High
Court in that case did not consider the aspect of disastrous
consequences considering competing drugs were for same ailments.
The appellant further contended that the competing drugs are for
different ailments/different cancers and administration of one for
another can lead to disastrous consequences and that the learned trial
Court erroneously considered that the competing drugs are for same
ailment. It was submitted on behalf of the appellant that the learned
trial Court did not consider the judgment <a href="/doc/15654482/" id="a_10">Novartis AG vs. Crest




<span class="hidden_text" id="span_37">FAO 447/2018                                                Page 37 of 87</span>
 Pharma Pvt. Ltd. and Ors</a>. 2009 (41) PTC 57 (Del) (SJ) and Charak
Pharma. Vs. Glenmark Pharmaceuticals; 2014 (57) PTC 538 (Bom)
to contend that it is more dangerous if a similar trade mark is used for
drugs used to cure different ailments.
</p><p id="p_100">32.   The appellant has further submitted that the learned trial Court
had disregarded the order dated 08.05.2018 of this Court in suit titled
as Sun Pharma Laboratories vs. (1) MSN Laboratories and (2) Intas
Pharmaceuticals in CS (COMM) No.637/2018 which had injuncted
this very defendant/respondent from dealing in medicinal preparations
under the mark MIRATAS (for treatment of overactive bladder),
which was found to be deceptively similar to MIRTAZ i.e. for
treatment of depression and in that case, this Court injuncted the
defendant/respondent after observing that the two trademarks are more
or less identical but being used for treatment of separate diseases and
which would gravely endanger the health of the public. The appellant
also contended that the verdicts in <a href="/doc/154833956/" id="a_11">Schering Corporation and Ors. vs.
Alkem Laboratories Ltd</a>.; 2010 (42) PTC 772 (Del) (DB) and
Astrazeneca UK Ltd. and Anr. Vs. Orchid Chemicals and
Pharmaceuticals Ltd.; (2007) ILR 1 Delhi 874 (DB) were not on
facts pari materia to the instant case, as in that case the disastrous
consequences of two drugs being in relation to the same treatment and
of the disastrous consequence of the competing drugs had not been
considered.
</p><p id="p_101">33.   The appellant further submitted that in the field of medicinal
remedies, the Courts should not speculate as to whether there is a
probability of confusion between similar names and that the



<span class="hidden_text" id="span_38">FAO 447/2018                                               Page 38 of 87</span>
 learned trial Court had failed to consider that people had died on
account of wrongs drugs having been dispensed against written
prescriptions. Inter alia the appellant submitted that the confusion can
occur at any level and it can occur at the time of dispensation of the
medicine by the pharmacist, at the para medical level and that the
competing medicines are administered by oncologists and their para
medical staff and that confusion can occur considering both are cancer
drugs though for different cancers.
</p><p id="p_102">34.   Inter alia the appellant submitted that vide the impugned order
the learned trial Court erroneously made a side by side comparison of
the competing packagings to test visual similarity and it is submitted
on behalf of the appellant that the same is against the test of
infringement and that the learned trial Court failed to consider that the
customer buying the product neither has the benefit of side by side
comparison nor does he know the molecules/salt or the difference
between the competing salts and that the Doctor&#x27;s prescription does
not carry the image/ trade dress/ packaging of the drug prescribed nor
does it suggest the name of the salt that the requisite drug would
contain. The appellant reiterated that the competing marks BEVETEX
and Bevatas are too close on account of both prefix and suffix of the
competing marks being similar and it was reiterated on behalf of the
appellant that the impugned mark is likely to cause confusion leading
to disastrous consequences. Reliance was placed on behalf of the
appellant on the verdict of this Court in <a href="/doc/1806604/" id="a_12">Automatic Electric Limited
vs. R. K. Dhawan and Ors</a>., 77 (1999) DLT 292 (SJ) with specific
reference to para-19 thereof which reads to the effect that:
</p>


<span class="hidden_text" id="span_39">FAO 447/2018                                                   Page 39 of 87</span>
<blockquote id="blockquote_25">       &quot;19. It is undoubtedly true that the first syllable of a
      work mark is generally the most important and thus,
      when the defendants are using a similar prefix with that
      of the plaintiff with a little variation in the suffix part of
      it, in my considered opinion, the trademarks are
      deceptively similar and cause of action for prima facie
      infringement is complete....&quot;
</blockquote>

<p id="p_103">35.   On behalf of the appellant, reliance was placed on the verdict of
Charak Pharma Pvt. Ltd. Vs. Glenmark Pharmaceuticals Ltd., 2014
(57) PTC 538 (Bom), to contend that the public interest would support
lesser degree of proof showing confusing similarity in the case of
trade mark in respect of medicinal products as against other non-
medicinal products and in as much as drugs are poisons, not sweets
and confusion between medicinal products may be life threatening, not
merely inconvenient with specific reliance placed on para 22.1 of the
said verdict, which reads to the effect : -
</p>
<blockquote id="blockquote_26">      &quot;9.7 Without prejudice to the aforestated contentions,
      even if this Court holds that the marks are similar, there is
      no likelihood of any confusion/deception between the two
      marks in question, since there is a widespread use of the
      prefix/suffix &quot;NOVA&#x27;&#x27; by several traders in the
      pharmaceutical trade and the purchasing members will
      tend to ignore and/or gloss over and/or give less
      importance to the common features and will always pay
      more regard to the uncommon part. The Defendant has
      set out the differences in the salient features between the
      two products qua its use, packaging, display on cartons,
      catch cover on blister pack and price and has submitted
      that this added material is sufficient to distinguish the two
      products and rules out the question of passing off. In




<span class="hidden_text" id="span_40">FAO 447/2018                                                  Page 40 of 87</span>
      support, the Defendant has relied on the decision of the
     Hon&#x27;ble Supreme Court in the case of <a href="/doc/529384/" id="a_13">Kaviraj Pandit
     Durga Dutt Sharma vs. Navaratna Pharmaceutical</a> AIR
     1965 SC 980. The Defendant has also submitted that
     though the Defendant has been selling its products since
     May, 2006, however, till date the Defendant has not
     received any complaint of confusion or deception between
     its products and that of the Plaintiff.
</blockquote>
<blockquote id="blockquote_27">     ..
</blockquote>
<blockquote id="blockquote_28">     ..
</blockquote>
<blockquote id="blockquote_29">     ..
</blockquote>
<blockquote id="blockquote_30">     22.1        Applying       the    aforesaid     tests    and
     considering the Plaintiff&#x27;s and Defendant&#x27;s mark as a
     whole, and for the reasons set out hereinabove, I am
     prima facie satisfied that the Defendant&#x27;s mark
     &quot;ECONOVA&quot; is deceptively similar to the Plaintiff&#x27;s mark
     &quot;EVANOVA&quot;. In fact, the Plaintiff&#x27;s product is an
     ayurvedic preparation in the form of capsules for
     treatment of menopause. On the other hand, the
     Defendant&#x27;s product is entirely different and is a medicine
     for treatment of bacterial vaginosis. If, as a result of the
     confusion, the wrong drug is administered, it would lead
     to disastrous consequences. The Hon&#x27;ble Supreme Court
     while noting this aspect has clearly held that when the
     drugs have marked differences in their compositions with
     completely different side effects, the test should be applied
     strictly as the possibility of harm resulting from any kind
     of confusion by the consumer can have unpleasant if not
     disastrous results. In the words of the Hon&#x27;ble Supreme
     Court, &quot;Public interest would support lesser degree of
     proof showing confusing similarity in the case of trade
     marks in respect of medicinal products as against other
     non-medicinal products. Drugs are poisons, not sweets.
     Confusion between medicinal products may, therefore, be
     life threatening, not merely inconvenient&quot;. &quot;
</blockquote>


<span class="hidden_text" id="span_41">FAO 447/2018                                              Page 41 of 87</span>
<p id="p_104"> 36.    Reliance was also placed on behalf of the appellant on the
verdict of this Court in <a href="/doc/15654482/" id="a_14">Novartis AG vs. Crest Pharma Pvt. Ltd. and
Anr. MIPR</a> 2010 (1) 44 to contend that that the drugs in question
being marketed by the appellant and the respondent within the domain
of Schedule &#x27;H&#x27; are to be purchased by the customers only on the
prescription of a medical practitioner, the same does not suffice to
detract from the merits of the contentions of the appellant that there
can be misguidance which arises in view of the descriptively similar
trade marks and that such an urgency warrants the ground of the
prayer made by the petitioner. Reliance was placed on behalf of the
appellant to specific observations in para 25 of this verdict which
reads to the effect :-
</p>
<blockquote id="blockquote_31">      &quot;25. The third contention of the learned counsel for the
      defendant is that the product of the parties in question is
      Schedule &quot;H&quot; drug and the same has to be purchased by
      the customers only on the prescription of medical
      practitioner. The argument of the defence of Schedule
      &quot;H&quot; drug has already been dealt with in various cases
      decided by the High Courts as well as the Apex court
      wherein the court has rejected the said submission many
      times. In the case of Cadila Pharmaceuticals (supra) in
      para 22 and 28 it was held as under :
</blockquote>
<blockquote id="blockquote_32">      &quot;22. It may here be noticed that Schedule &quot;H&quot; drugs are
      those which can be sold by the chemist only on the
      prescription of the Doctor but Schedule &quot;L&quot; drugs are not
      sold across the counter but are sold only to the hospitals
      and clinics. Nevertheless, it is not un-common that
      because of lack of competence or otherwise, mistakes can
      arise specially where the trade marks are deceptively
      similar. In Blansett Pharmaceuticals Co. Vs. Carmick



<span class="hidden_text" id="span_42">FAO 447/2018                                              Page 42 of 87</span>
       Laboratories Inc. 25 USPQ 2nd, 1473 (TTAB 1993), it
      was held as under:
</blockquote><blockquote id="blockquote_33">      &quot;Confusion and mistake is likely, even for prescription
      drugs prescribed by doctors and dispensed by pharmacists,
      where these similar goods are marketed under marks
      which look alike and sound alike&quot;.&quot;
</blockquote>

<p id="p_105">37.    Reliance was placed on behalf of the appellant on the verdict of
the Hon&#x27;ble Supreme Court in Cadila Health Care Ltd. Vs. Cadila
Pharmaceuticals Ltd. AIR 2001 SC 1952 to contend that exacting
judicial scrutiny is required if there is a possibility of confusion over
marks on medicinal products because the potential harm may be far
more dire than that in confusion over ordinary consumer products and
reliance was placed on the observations in the said verdict in para 39,
which reads to the effect : -
</p>
<blockquote id="blockquote_34">      &quot;39. Public interest would support lesser degree of
      proof showing confusing similarity in the case of trade
      mark in respect of medicinal product as against other
      non-medicinal products. Drugs are poisons, not sweets.
      Confusion between medicinal products may, therefore, be
      life threatening, not merely inconvenient. Noting the
      frailty of human nature and the pressures placed by
      society on doctors, there should be as many clear
      indicators as possible to distinguish two medicinal
      products from each other. It is not uncommon that in
      hospitals, drugs can be requested verbally and/or under
      critical/pressure situations. Many patients may be elderly,
      infirm or illiterate. They may not be in a position to
      differentiate between the medicine prescribed and bought
      which is ultimately handed over to them. This view finds
      support from McCarthy on Trade Marks, 3rd Edition,
      para 23.12 of which reads as under:
</blockquote>



<span class="hidden_text" id="span_43">FAO 447/2018                                                Page 43 of 87</span>
<blockquote id="blockquote_35">       The tests of confusing similarity are modified when the
      goods involved are medicinal products. Confusion of
      source or product between medicinal products may
      produce physically harmful results to purchasers and
      greater protection is required than in the ordinary case.
      If the goods involved are medicinal products each with
      different effects and designed for even subtly different
      uses, confusion among the products caused by similar
      marks could have disastrous effects. For these reasons, it
      is proper to require a lesser quantum of proof of
      confusing similarity for drugs and medicinal
      preparations. The same standard has been applied to
      medical products such as surgical sutures and clavicle
      splints.&quot;
</blockquote>
<p id="p_106">38.   Reliance was also placed on behalf of the appellant on the
factors spelt out in the said verdict essentially to be taken into account
deciding a similar question which is so observed in paras 42 to 44 of
the said verdict, which reads to the effect : -
</p>
<blockquote id="blockquote_36">      &quot;42. Broadly stated in an action for passing off on the
      basis of unregistered trade mark generally for deciding
      the question of deceptive similarity the following factors
      to be considered:
</blockquote>
<blockquote id="blockquote_37">      a) The nature of the marks i.e. whether the marks are
      word marks or label marks or composite marks, i.e. both
      words and label works.
</blockquote>
<blockquote id="blockquote_38">      b) The degree of resembleness between the marks,
      phonetically similar and hence similar in idea.
</blockquote>
<blockquote id="blockquote_39">      c) The nature of the goods in respect of which they are
      used as trade marks.
</blockquote>
<blockquote id="blockquote_40">      d) The similarity in the nature, character and
      performance of the goods of the rival traders.
</blockquote>



<span class="hidden_text" id="span_44">FAO 447/2018                                                 Page 44 of 87</span>
<blockquote id="blockquote_41">       e) The class of purchasers who are likely to buy the
      goods bearing the marks they require, on their education
      and intelligence and a degree of care they are likely to
      exercise in purchasing and/or using the goods.
</blockquote>
<blockquote id="blockquote_42">      f) The mode of purchasing the goods or placing orders
      for the goods and

</blockquote><blockquote id="blockquote_43">      g) Any other surrounding circumstances which may be
      relevant in the extent of dissimilarity between the
      competing marks.
</blockquote>
<blockquote id="blockquote_44">      43.    Weightage to be given to each of the aforesaid
      factors depends upon facts of each case and the same
      weightage cannot be given to each factor in every case.
</blockquote>
<blockquote id="blockquote_45">      44.     The trial court will now decide the suit keeping in
      view the observations made in this judgment. No order
      as to costs.&quot;
</blockquote>
<p id="p_107">39.    Reliance was also placed on behalf of the appellant on the
verdict of Hon&#x27;ble Supreme Court in Wockhardt Limited Vs. Torrent
Pharmaceuticals Ltd. and Anr. in Civil Appeal No. 9844 of 2018 to
contend that the defendant&#x27;s state of mind is wholly irrelevant to the
existence of the cause of action in passing off and in an action based
on deceit, fraud is not a necessary element of a right of action.
</p><p id="p_108">40.    On behalf of the respondent, reliance was placed on the verdict
of Division Bench of this Court in Gufic Ltd. and Anr. Vs. Clinique
Laboratories, LLC and Anr. MIPR 2010 (2) 411 to contend that in
case of an infringement, principles have been culled out, which are to
the effect : -
</p>
<blockquote id="blockquote_46">      &quot;22. The following principles can be culled out from the
      aforesaid decisions:-
</blockquote>


<span class="hidden_text" id="span_45">FAO 447/2018                                                 Page 45 of 87</span>
<blockquote id="blockquote_47">       1. The test of deceptive similarity in the case of
      infringement is the same as in a passing off action,
      where the marks are not identical;
</blockquote><blockquote id="blockquote_48">      2. The question has to be approached from the point of
      view of a man with average intelligence and imperfect
      recollection;
</blockquote><blockquote id="blockquote_49">      3. In comparing the marks, it is the overall structural
      and phonetic similarity of the two marks that is to be
      seen and not by splitting them into their component
      parts and to consider the etymological meaning thereof;
</blockquote><blockquote id="blockquote_50">      4. The trademark is the whole thing - the whole word
      has to be considered; and
</blockquote><blockquote id="blockquote_51">      5. In comparing the two marks, it is also to be seen
      whether they both convey the same idea - (test of
      commonness of the idea between the two marks).&quot;
</blockquote>

<p id="p_109">and that the overall structure and phonetic similarity of two marks
have essentially to be compared and the marks cannot be separated
and the mark of each i.e. the appellant and the respondent herein are to
be taken up together whilst making a comparison and if there cannot
be splitting up of the mark even if there is no phonetic structure or
phonetic similarity visually in the two marks. Vide the said verdict
another important circumstance taken into account is the price
differential between two products with observation to the effect that
price differential is so vast that no consumer of products of either the
appellant or the respondent would confuse one for the other and, prima
facie, a case of infringement cannot be held to be have been made out.
</p>
<p id="p_110">41.   Reliance was also placed on behalf of the respondent on the
verdict of Division Bench of this Court in Schering Corporation and
Ors. Vs. Almen Laboratories Ltd. 2010 42 PTC 772 (Del) with



<span class="hidden_text" id="span_46">FAO 447/2018                                               Page 46 of 87</span>
 specific reliance on observations in paras 2, 3, 6, 100 and 103 of this
said verdict to the effect : -
</p>
<blockquote id="blockquote_52">      &quot;2. These interim applications had been filed to seek
      grant of an interim injunction to restrain the
      Respondent Alkem Laboratories Ltd. (Defendant in
      CS(OS) NO. 730/2007) (hereinafter referred to as
      ALKEM) and Getwell Sciences India Pvt. Ltd (
      Defendant in Suit No. 361/2007) (hereinafter referred to
      as GETWELL) from using the marks TEMOKEM and
      TEMOGET respectively in relation to their
      pharmaceutical products - the active ingredient whereof
      is TEMOZOLOMIDE, a drug administered for the
      treatment of brain cancer.
</blockquote>
<blockquote id="blockquote_53">      3. The appellants filed the aforesaid two suits to, inter
      alia, seek permanent injunction to restrain infringement
      of registered trademarks, copyright, passing off, dilution,
      unfair competition, rendition of accounts of profits,
      deliver-up etc. against the aforesaid respondents
      ALKEM &amp; GETWELL respectively.
</blockquote>
<blockquote id="blockquote_54">      ..
</blockquote>
<blockquote id="blockquote_55">      ..
</blockquote>
<blockquote id="blockquote_56">      6. The appellants claim to have came to know that the
      respondent ALKEM was marketing and selling an
      almost identically positioned drug (for treatment of
      brain cancer or glioblastoma multiforme) under the
      mark TEMOKEM which, according to the appellants,
      was phonetically, linguistically, textually, visibly,
      manifestly, confusingly and deceptively similar to their
      marks TEMODAL/TEMODAR. They also came to know
      that the respondent ALKEM had submitted a &quot;Proposed
      to be used&quot; application bearing number 1348168 in class
      5 for registration of the mark TEMOKEM and the same
      was advertised in Trademark Journal no. 1335-0 dated




<span class="hidden_text" id="span_47">FAO 447/2018                                               Page 47 of 87</span>
      01.11.2006 made available to the public on 03.03.2007.
     In answer to this, the appellants have filed a notice of
     opposition dated 23.03.2007 to the above application and
     the same is still pending.
</blockquote>
<blockquote id="blockquote_57">     ...
</blockquote>
<blockquote id="blockquote_58">     ...
</blockquote>
<blockquote id="blockquote_59">     ...
</blockquote>
<blockquote id="blockquote_60">     100. <a href="/doc/1114158/" id="a_15">In Cadila Health Care Ltd. V. Cadila
     Pharmaceuticals Ltd</a>. (supra) the two competing
     trademarks were &#x27;FALCIGO&#x27; of the plaintiff and
     &#x27;FALCITAB&#x27; of the defendant. Both the drugs were
     meant to cure cerebral malaria commonly known as
     falcipharum. The drugs were schedule -&#x27;L&#x27; drugs which
     means, that the drugs were not at all available for sale in
     retail and could be supplied only to hospitals and clinics.
     Consequently, there was even stricter regime for the sale
     of such drugs when compared to Schedule -&#x27;H&#x27; drugs.
     There was also substantial price difference in the two
     drugs. The Trial Court as well as the High Court (in
     First Appeal) found that the packaging and getup of the
     two products was not deceptively similar or confusing.
     The extra Assistant Judge, Vadodra declined the interim
     injunction sought by the plaintiff. This order was upheld
     in First Appeal. The Supreme Court also declined to
     interfere with the order. The reasons given by the
     Supreme Court for its decision, and the principles to be
     kept in mind while dealing with an action for
     infringement or passing off, specifically in the cases
     relating to medical products, were subsequently set out
     by the Supreme Court in the aforesaid judgment. The
     Court did not grant the interim injunction for the reason
     that it felt that there was possibility of evidence being
     required on merits of the case. The Court felt that
     expression of opinion on merits of the case by the




<span class="hidden_text" id="span_48">FAO 447/2018                                              Page 48 of 87</span>
       Supreme Court at the interlocutory stage would not be
      advisable.
</blockquote>
<blockquote id="blockquote_61">      ..
</blockquote>
<blockquote id="blockquote_62">      ..
</blockquote>
<blockquote id="blockquote_63">      103. As we have already noticed, the present is an action
      for infringement under <a href="/doc/84096/" id="a_16">Section 29</a> of the Act and not an
      action for passing off. In any event, on consideration of
      the various factors set out by the Supreme Court, as
      aforesaid, to us it is clear that keeping in view the nature
      of the marks-which are word marks; the lack of
      resemblance between the marks-phonetic or otherwise;
      the fact that the word fragment &#x27;TEMO&#x27; is publici juris
      for the generic term TEMOZOLOMIDE, which is the
      active ingredient in the appellants drugs and the use of
      &#x27;TEMO&#x27; is, therefore, descriptive; the fact that the
      appellants cannot appropriate to themselves the
      exclusive use of a generic term which is publici juris and
      descriptive; the fact that the drugs in question are
      Schedule-H drugs and that there are vast price
      differences, we are of the view that the injunction earlier
      granted in favour of the appellants in the two cases have
      rightly been vacated by the learned Single Judge.&quot;
</blockquote>
<p id="p_111">42.    Reliance was also placed on behalf of the respondent on the
verdict of the Division Bench of this Court in Astrazeneca UK
Limited and Ors. Vs. Orchid Chemicals and Pharmaceuticals Ltd.
(2007) ILR 1 Delhi 874, to contend that trade marks are to be taken as
a whole and not to be broken up separately. Reliance was thus placed
on behalf of the respondent with specific observations in paras 19, 20,
21, 22, 23 of the said verdict, which reads to the effect : -
</p>
<blockquote id="blockquote_64">      &quot;19. Admittedly, &#x27;Mero&#x27;, which is common to both the
      competing    marks,     is  taken    by  both    the



<span class="hidden_text" id="span_49">FAO 447/2018                                                    Page 49 of 87</span>
      appellants/plaintiffs and the respondent/ defendant from
     the drug &#x27;Meropenem&#x27;, taking the prefix &#x27;Mero&quot; which
     is used as a prefix in both the competing marks. Both the
     appellants/plaintiffs and the respondent/defendant are
     marketing the same molecule &#x27;Meropenem&#x27;. Neither the
     appellants/plaintiffs nor the respondent/defendant can
     raise any claim for exclusive user of the aforesaid word
     &#x27;Meropenem&#x27;. Along with the aforesaid generic/common
     prefix, &#x27;Mero&#x27;, the appellants/plaintiffs have used the
     syllables &#x27;nem&#x27;, whereas, the respondent/defendant has
     used the syllable &#x27;mer&#x27;. It is true that the aforesaid
     words/trade names cannot be deciphered or considered
     separately, but must be taken as a whole. But even if
     they are taken as a whole, the prefix &#x27;Mero&#x27; used with
     suffix in the two competing names, distinguishes and
     differentiates the two products. When they are taken as a
     whole, the aforesaid two trade marks cannot be said to
     be either phonetically or visually or in any manner
     deceptively similar to each other.
</blockquote>
<blockquote id="blockquote_65">     20. We are informed that there are a number of such
     other similar names with the prefix &#x27;Mero&#x27; which are in
     the market. They were also taken notice of by the
     learned Single Judge while dealing with the injunction
     application. In the decisions of the Supreme Court and
     this Court also, it has been clearly held that nobody can
     claim exclusive right to use any word, abbreviation, or
     acronym which has become publici juris. In the trade of
     drugs, it is common practice to name a drug by the name
     of the organ or ailment which it treats or the main
     ingredient of the drug. Such an organ ailment or
     ingredient being publici Juris or generic cannot be
     owned by anyone exclusively for use as a trade mark. In
     the Division Bench decision of this Court in SBL
     Limited (supra) it was also held that possibility of
     deception or confusion is reduced practically to nil in
     view of the fact that the medicine will be sold on medical
     prescription and by licensed dealers well versed in the
     field and having knowledge of medicines. It was further



<span class="hidden_text" id="span_50">FAO 447/2018                                             Page 50 of 87</span>
      held that the two rival marks, &#x27;Liv.52&#x27; and &#x27;LIV-T&#x27;,
     contain a common feature, &#x27;Liv&#x27; which is not only
     descriptive, but also publici Jurisdiction and that a
     customer will tend to ignore the common feature and
     will pay more attention to uncommon features i.e. &#x27;52&#x27;
     and &#x27;T&#x27; and that the two do not have such phonetic
     similarity so as to make it objectionable.
</blockquote>
<blockquote id="blockquote_66">     21. In our considered opinion the facts of the said case
     are almost similar and squarely applicable to the facts of
     the present case. &#x27;Meropenem&#x27; is the molecule which is
     used for treatment of bacterial infections. In that view of
     the matter, the abbreviation &#x27;Mero&#x27; became a generic
     term, is publici Juris and it is distinctive in nature.
     Consequently, the appellants/plaintiffs cannot claim
     exclusive right to the use of &#x27;Mero&#x27; as constituent of any
     trademark. The possibility of deception or confusion is
     also reduced practically to nil in view of the fact that the
     medicine is sold only on prescription by dealers. The
     common feature in both the competing marks i.e. &#x27;Mero&#x27;
     is only descriptive and publici Juris and, therefore, the
     customers would tend to ignore the common feature and
     would pay more attention to the uncommon feature.
     Even if they are expressed as a whole, the two did not
     have any phonetic similarity to make it objectionable.
     There are at least four other registered users of the
     prefix &#x27;Mero&#x27; in India whereas the names of 35
     companies using &#x27;Mero&#x27; trademarks, which have been
     registered or applied for registration, have been
     furnished in the pleadings. The respondent/defendant
     advertised its trademark &#x27;Meromer&#x27; after submitting its
     application for registration and at that stage, there was
     no opposition even from the appellants/plaintiffs. The
     trademark of the respondent/defendant was registered
     there being no opposition from any quarter, including
     the appellants/plaintiffs.
</blockquote>
<blockquote id="blockquote_67">     22. Consequently, the two names, namely, &#x27;Meromer&#x27;
     and &#x27;Meronem&#x27; are found to be prima facie dissimilar to



<span class="hidden_text" id="span_51">FAO 447/2018                                               Page 51 of 87</span>
       each other. They are Schedule-H drugs available only
      on doctor&#x27;s prescription. The factum that the same are
      available only on doctor&#x27;s prescription and not as an
      over the counter medicine is also relevant and has been
      rightly taken note of by the learned Single Judge. In our
      considered opinion, where the marks are distinct and the
      features are found to be dis-similar, they are not likely to
      create any confusion. It is also admitted by the parties
      that there is a difference in the price of the two products.
      The very fact that the two pharmaceutical products, one
      of the appellants/plaintiffs and the other of the
      respondent/ defendant, are being sold at different prices
      itself ensures that there is no possibility of any
      deception/confusion, particularly in view of the fact that
      customer who comes with the intention of purchasing
      the product of the appellants/plaintiffs would never settle
      for the product of the respondent/defendant which is
      priced much lower. It is apparent that the trademarks on
      the two products, one of the appellants/plaintiffs and the
      other of the respondent/defendant, are totally dissimilar
      and different.
</blockquote>
<blockquote id="blockquote_68">      23. Consequently, we find no infirmity with the findings
      arrived at by the learned Single Judge at this stage,
      which are prima facie in nature. The learned Single
      Judge was justified in not granting temporary injunction
      in favor of the appellants/plaintiffs and directing
      defendant/respondent to maintain accounts of the sale.
      We, therefore, dismiss this appeal leaving the parties to
      bear their own costs.&quot;
</blockquote>
<p id="p_112">43.   Reliance was also placed on behalf of the respondent on the
verdict of Division Bench of this Court in Sun Pharmaceutical
Industries Ltd. Vs. Anglo French Drugs &amp; Industries Ltd. 2014 SCC
OnLine Del 4716 to contend that in terms of the verdict in <a href="/doc/330608/" id="a_17">Wander
Ltd. and Anr. v. Antox India P. Ltd</a>.: 1990 (Supp) SCC 1 727, there




<span class="hidden_text" id="span_52">FAO 447/2018                                                Page 52 of 87</span>
 is no ground for variation of the order made by the Trial Court and
there is no infirmity in the impugned order taking into account the
factum that the active ingredient of the product of the appellant and
the respondent are different, the prices of the two products are
different, their scheme and trade members are different and the
ailment that they treat is different.
</p><p id="p_113">44.   It was also submitted on behalf of the respondent that the
contentions raised on behalf of the appellant that there was a
likelihood of confusion cannot be accepted in as much as even qua the
contention that has been raised on behalf of the appellant that there has
been a confusion at one stage in administration of the drug due to
similarity in name of the drug of the appellant and the respondent, no
such circumstance has been specified on behalf of the appellant, qua
which it was submitted on behalf of the appellant by the learned
counsel for the appellant that the same cannot be put forth by the
appellant due to professional reasons.
</p><p id="p_114">45.   Written submissions have also been submitted on behalf of
either side. Through the written submissions of the appellant it has
been sought to be reiterated that the plaintiff&#x27;s i.e. the appellant&#x27;s mark
Beve in BEVETEX is arbitrary not derived from the salt Paclitaxel
and that the competing drugs BEVETEX and BEVATAS are for
different cancers and both are injections and administration of one for
another can lead to disastrous consequences i.e. causing of Gastro
Intestine Perforation i.e. creating holes in the stomach which would
eventually prove fatal. The appellant reiterates that the suit has been
filed purely in public interest and that it has no commercial interest



<span class="hidden_text" id="span_53">FAO 447/2018                                                  Page 53 of 87</span>
 and that it has given up its relief for rendition of accounts before the
learned trial Court.
</p><p id="p_115">46.   Inter alia the appellant submits that the defendant&#x27;s i.e. the
respondent&#x27;s mark has not been claimed to be used, whereas the
appellant i.e. the plaintiff is a prior user since 2015 of the registered
trade mark, registered in 1983.
</p><p id="p_116">47.   The appellant submits that though the respondent has contended
that there is no possibility of confusion as the drug is administered by
a specialized doctor and the staff, confusion can occur at any level and
it can occur at the time of dispensation of the medicine by the
pharmacist, at the para medical level and that competing medicines are
administered by oncologists and their para medical staff and that
confusion can occur considering both are cancer drugs though for
different cancers. Inter alia the appellant submits that such an
argument could have been raised that one medicine is administered by
a general physician/ gynecologist etc. and the other by oncologists and
their staff and that no confusion would take place because the
respective doctors may know their medicines but in the instant case
there is no such situation.
</p><p id="p_117">48.   The appellant further submits that there have been reported
cases where people had died on account of wrong drugs having been
dispensed despite of their being prescription of schedule drugs and
that the prescription does not contain the name of the salt or the trade
dress/ packaging of the drug and that the competing marks are not to
be compared side by side. Inter alia the appellant has contended that
the test of confusion that is to be seen if an average person with



<span class="hidden_text" id="span_54">FAO 447/2018                                                Page 54 of 87</span>
 imperfect recollection would get confused. Inter alia the appellant
submits that the consumer/patient does not know the difference
between the salt and in fact one cannot even pronounce the competing
salts/molecules and that to be able to distinguish between the two is
not possible.
</p><p id="p_118">49.    Reliance was placed on behalf of the appellant on the verdict of
the Hon&#x27;ble Supreme Court in Corn Products Refining Co. Vs.
Shangrila Food Products Ltd., AIR 1960 SC 142 with reference to
para-20 which reads to the effect that:
</p>
<blockquote id="blockquote_69">      &quot;.......Again, in deciding the question of similarity between
      the two marks we have to approach it from the point of view
      of a man of average intelligence and of imperfect
      recollection. To such a man the overall structural and
      phonetic similarity and the similarity of the idea in the two
      marks is reasonable likely to cause a confusion between
      them.&quot;
</blockquote><p id="p_119">50.    The appellant further submits that the para medical staff of a
hospital was about to administer the plaintiff&#x27;s i.e. the appellant&#x27;s drug
in place of the defendant&#x27;/respondent&#x27;s drug on account of confusion
and that the plaintiff i.e. the appellant cannot give the name of the
hospital in the pleadings as the same would lead to blacklisting of the
product of the plaintiff by the said hospital and the other hospitals.
The appellant further submits that the Court does not have to see the
actual confusion but likelihood of confusion and in the field of
medicinal remedies, the Courts may not speculate as to whether there
is a probability of confusion between similar names and reliance was
thus placed on Cadila (Supra) wherein injunction was refused by the




<span class="hidden_text" id="span_55">FAO 447/2018                                                 Page 55 of 87</span>
 District Court and the High Court and the Hon&#x27;ble Supreme Court
remanded the matter back to the District Court with specific reference
to paras-34, 35 &amp; 39 of the said verdict which have already been
adverted to elsewhere hereinabove.
</p>
<p id="p_120">51.    Inter alia the appellant submits that the judgments relied upon
on behalf of the respondent are distinguishable inasmuch as in none of
these judgments, the Courts considered the aspect of disastrous
consequences since competing drugs were not for the same ailment
and were not derived from the same salt.
</p>
<p id="p_121">52.    Inter alia a contention was also raised on behalf of the
appellant, that if the same trade mark apparently a reference to a
similar trade mark is used for different ailment, the same is more
dangerous. Reliance is placed on behalf of the appellant on the verdict
of this Court in Novartis AG Vs. Crest Pharma Pvt. Ltd. and Ors.
2009 (41) PTC 57 (Del) with specific reference to paras-21, 22, 23, 25
of the said verdict which read to the effect that:
</p>
<blockquote id="blockquote_70">      &quot;21. The second contention of the defendant is that the
      plaintiff&#x27;s drug is prescribed for urinary respiratory track
      infection and acute otitis media whereas the defendant&#x27;s
      product being an antibiotic is prescribed mostly for post
      operative cases and the ingredients of the two products are
      also different and used for different purposes of disease.
      The defendant has also contended that the plaintiff&#x27;s
      product is used in tablet and oral suspension form whereas
      the defendant&#x27;s product is only available in injection form,
      therefore, there is no confusion and deception between the
      two products in question.
</blockquote>



<span class="hidden_text" id="span_56">FAO 447/2018                                               Page 56 of 87</span>
<blockquote id="blockquote_71">      22. I do not accept the submission of the learned counsel for
     the defendant as I feel that it is more dangerous if the
     pharmaceuticals products bearing the same mark is used
     for different purposes for the same ailment or even
     otherwise. I also do not accept the contention of the
     defendant&#x27;s counsel that there would be no confusion if the
     products contain different ingredients/different salt. In my
     opinion, it is more dangerous and harmful in the trade if the
     same trade mark is used for different ailments. The Apex
     court has already dealt with this proposition of law in the
     case of Cadila Healthcare Ltd. Vs. Cadila Pharmaceuticals,
     (2001) 5 SCC 73 and held as under :
</blockquote>
<blockquote id="blockquote_72">     23. The other argument of the counsel for the defendant that
     the plaintiff&#x27;s product is available in tablets and oral
     suspension form and the defendant&#x27;s product is available in
     injection form has also no force as it has been seen from
     experience of the pharmaceuticals products available in all
     over the world that most of the companies are making
     pharmaceuticals products in both the forms i.e. tablets as
     well as in injection form under the same trade mark. As per
     well settled law, the actual confusion and deception is not
     required in order to prove the case of passing off even if the
     defendant has adopted the mark innocently and the court
     comes to the conclusion that the two trade marks are
     deceptively similar, injunction under the said circumstances
     has to be granted. Actual deception is not required in an
     action of passing off. <a href="/doc/1181080/" id="a_18">Century Traders vs. Roshan Lal
     Duggar &amp; Co</a>., AIR 1978 (Del) 250. Therefore there is no
     chance of confusion and deception.
</blockquote>
<blockquote id="blockquote_73">     ..
</blockquote>
<blockquote id="blockquote_74">     25. The third contention of the learned counsel for the
     defendant is that the product of the parties in question is
     Schedule &quot;H&quot; drug and the same has to be purchased by the
     customers only on the prescription of medical practitioner.
     The argument of the defence of Schedule &quot;H&quot; drug has
     already been dealt with in various cases decided by the



<span class="hidden_text" id="span_57">FAO 447/2018                                                Page 57 of 87</span>
       High Courts as well as the Apex court wherein the court has
      rejected the said submission many times. In the case of
      Cadila Pharmaceuticals (supra) in para 22 and 28 it was
      held as under :
</blockquote>
<blockquote id="blockquote_75">         &quot;22. It may here be noticed that Schedule &quot;H&quot; drugs are
         those which can be sold by the chemist only on the
         prescription of the Doctor but Schedule &quot;L&quot; drugs are
         not sold across the counter but are sold only to the
         hospitals and clinics. Nevertheless, it is not un-common
         that because of lack of competence or otherwise,
         mistakes can arise specially where the trade marks are
         deceptively similar. In Blansett Pharmaceuticals Co. Vs.
         Carmick Laboratories Inc. 25 USPQ 2nd, 1473 (TTAB
         1993), it was held as under:
</blockquote><blockquote id="blockquote_76">           &quot;Confusion and mistake is likely, even for prescription
           drugs prescribed by doctors and dispensed by
           pharmacists, where these similar goods are marketed
           under marks which look alike and sound alike&quot;.
</blockquote>
<p id="p_122">53.    Reliance was also placed on behalf of the appellant on the
verdict in Charak Pharma Pvt. Ltd. Vs. Glenmark Pharmaceuticals
Ltd., 2014 (57) PTC 538 (Bom) with specific reference to para-9.7
and 22.1 thereof which have already been adverted to hereinabove.
</p><p id="p_123">54.    Inter alia reliance was placed on behalf of the appellant on the
verdict of Hon&#x27;ble Supreme Court in Neon Laboratories Vs. Medical
Technologies Ltd. 2015 (64) PTC 225 (SC) with specific reference to
para-1, 9 &amp; 10 to contend that as the plaintiff had admittedly entered
the market prior to the respondent, the injunction ought to have been
granted by the learned trial Court on the &quot;First in the Market&quot;
principle. Reliance was further placed on behalf of the appellant on the
verdict of the Hon&#x27;ble Supreme Court in Wockhardt Limited Vs.




<span class="hidden_text" id="span_58">FAO 447/2018                                               Page 58 of 87</span>
 Torrent Pharmaceuticals Ltd. and Anr. in Civil Appeal No. 9844 of
2018 contents of which have already adverted to hereinabove.
</p><p id="p_124">55.   The appellant further submits that the examination report issued
by the trade mark registry is an electronic report obtained by a
mechanical process without application of mind and it is a result
thrown electronically within the internal data base and if search
reports are held to be conclusive, there is no need for the trade mark
registrar to invite oppositions and that if that is so, once there are no
conflicting marks shown in the examination report, the mark should be
automatically registered which is never the case and that the
respondent&#x27;s trade mark has been opposed by the plaintiff i.e. the
appellant herein which is still pending disposal.
</p><p id="p_125">56.   Inter alia the appellant submits that he is not claiming any right
in BEV and that marks are not to be dissected for the purpose of
comparison which is against the Anti-Dissection Rule and that marks
are required to be compared as a whole with reliance having been
placed on the verdict of this Court in Stiefel Laboratoties Vs. Ajanta
Pharma Ltd. 211 (2014) Dlt 296 wherein it has been submitted that
reference is being made to paragraphs 23 and 23.15 of the verdict of
the Division Bench of this Court in United Biotech Pvt. Ltd. Vs.
Orchid Chemicals and Pharmaceuticals Ltd. and Ors. 2012 (50)
PTC 433 (Del) DB which read to the effect that:
</p>
<blockquote id="blockquote_77">      &quot;23. No fault can also be found with the approach of the
      IPAB in comparing the two competing marks as a whole.
      That is in fact the rule and the dissection of a mark is an
      exception which is generally not permitted. The anti-
      dissection rule is based upon a common sense observation



<span class="hidden_text" id="span_59">FAO 447/2018                                                Page 59 of 87</span>
       of customer behaviour as explained in McCarthy on Trade
      Marks and Unfair Competition [J Thomas McCarthy, IV
      Ed., Clark Boardman Callaghan 2007] under the sub-
      heading     &quot;Comparing        Marks:      Differences and
      Similarities. The treatise further states:
      ...
</blockquote><blockquote id="blockquote_78">      ...
</blockquote><blockquote id="blockquote_79">      ...
</blockquote><blockquote id="blockquote_80">      ...
</blockquote><blockquote id="blockquote_81">      23.15 .... The typical shopper does not retain all of the
      individual details of a composite mark in his or her mind,
      but retains only an overall, general impression created by
      the composite as a whole. It is the overall impression
      created by the mark from the ordinary shopper&#x27;s cursory
      observation in the marketplace that will or will not lead to
      a likelihood of confusion, not the impression created from
      a meticulous comparison as expressed in carefully
      weighed analysis in legal briefs.&quot;
</blockquote><blockquote id="blockquote_82">      &quot;In litigation over the alleged similarity of marks, the
      owner will emphasize the similarities and the alleged
      infringer will emphasize the differences. The point is that
      the two marks should not be examined with a microscope
      to find the differences, for this is not the way the average
      purchaser views the marks. To the average buyer, the
      points of similarity are the more important that minor
      points of difference.
</blockquote><blockquote id="blockquote_83">      A court should not engage &quot;technical gymnastics&quot; in an
      attempt to find some minor differences between conflicting
      marks. However, where there are both similarities and
      differences in the marks, there must be weighed against
      one another to see which predominate.&quot;
</blockquote>
<p id="p_126">57.   Inter alia the appellant submits that BEVE in BEVETEX is
arbitrary; not derived from the salt Paclitaxel and that the defendant/
respondent herein having derived the impugned mark from the salt has




<span class="hidden_text" id="span_60">FAO 447/2018                                                Page 60 of 87</span>
 no relevance when the question is of public interest and safety.
Reliance was placed on behalf of the appellant on the verdict of this
Court in Cadila Healthcare Ltd. Vs. Aureate Healthcare Pvt. Ltd.
and Ors. 2012 (51) PTC 585 (Del) (SJ) with specific refence to
observations in paras 41,46,48-50 in which an ex parte injunction was
confirmed in relation to the defendant/respondent&#x27;s unregistered trade
mark PANTOBLOC against the plaintiff&#x27;s registered trade mark of
PANTODAC with the details of the case being to the effect:
</p>
<pre id="pre_10">      Particulars       Plaintiff              Defendant

      Trade Mark        PANTODAC               PANTOBLOC

      Registration      1996                   2006
                                               (pending)

      Use               1999                   2003

      Salt              Pantoprazole           Pantoprazole

</pre><p id="p_127">58.   Inter alia the appellant submitted that secondly BEVACIREL,
BEVAREST and BEVAZZA are not deceptively similar to Plaintiff&#x27;s
trade mark BEVETEX and thirdly, the various marks containing
prefix BEV had been applied for /pending before trade mark registry
did not prove that they are in use and that common to register does not
prove common to trade. Reliance was also placed on behalf of the
appellant on the verdict of this Court in Century Traders Vs. Roshan
Lai Duggar Co. AIR 1978 Delhi 250 Division Bench quoted with
approval The Supreme Court in Corn Products Refining Co. Vs.



<span class="hidden_text" id="span_61">FAO 447/2018                                               Page 61 of 87</span>
 Shangrila Food Products Ltd., AIR 1960 SC 142, which reads to
the effect:
</p><blockquote id="blockquote_84">         &quot;(13) The Supreme Court in <a href="/doc/1883538/" id="a_19">Corn Products Refining Co.
         v. Shangrila Food Products Ltd</a>., 1960 J1 SCR 968 laid
         down the mle vis-a-vis user of a mark as opposed to
         registration of mark. It observed that the onus of proving
         user is on the person who claims it. It did not approve of
         looking into the register of trade marks where a mark may
         be entered to be any proof of user. To quote from the
         speech of A.K. Sarkar, J. : &quot;Now, of course, the presence
         of a mark in the register does not prove its user at all. It
         is possible that the mark may have been registered but
         not used. It is not permissible to draw any inference as to
         their user from the presence of marks in the register.
</blockquote>
<p id="p_128">59.      The appellant further submitted that the plea of common use
would fail unless substantial usage by others persons is proven.
Reliance in relation thereto is placed on behalf of the appellant on the
verdict in <a href="/doc/81192/" id="a_20">Pidilite Industries Ltd. vs. S.M. Associates and Ors</a>. 2003
(5) Bom CR 295 with specific refence to observations in paras 53, 55
&amp; 58, which read to the effect:
</p><blockquote id="blockquote_85">      &quot;53. It is important to note at the outset that other than annexing
      cartons bearing the aforesaid marks with the suffix &quot;seal&quot;, there
      is no evidence produced as to its actual use much less the extent
      of its use. In paragraphs 26, 27 and 28 of the affidavit in rejoinder,
      the Plaintiff has categorically denied the existence of the said
      brands &quot;A-Seal&quot; &quot;Inn-Seal&quot; &quot;Jam-Seal&quot; &quot;Max-Seal&quot;. The Plaintiff
      has further stated that the brands are not in use much less in
      continuous or extensive use. It is further denied that the colour
      scheme is used by most of the manufacturers.&quot;
      ..
</blockquote><blockquote id="blockquote_86">      ..
</blockquote><blockquote id="blockquote_87">      55. In National Bell Company Vs. Metal Goods Manufacturing Co.
      (P) Ltd. &amp;Anr. AIR 1971 SC 898, the Supreme Court held :-
</blockquote>



<span class="hidden_text" id="span_62">FAO 447/2018                                                   Page 62 of 87</span>
<blockquote id="blockquote_88">             &quot;The plea of common use must fail, for, to establish it the
            use by other persons should be substantial. Though
            evidence was produced by the appellant companies to show
            that there were other bells in the market with Tiftv or 50
            inscribed on them, no evidence was led to show that the use
            of the word Fifty or the numeral 50 was substantial. In
            these circumstances, it is impossible to sustain the
            contention founded on Clause (c) of <a href="/doc/1021595/" id="a_21">Section 32</a>&quot;
            ..
</blockquote><blockquote id="blockquote_89">            ..
</blockquote><blockquote id="blockquote_90">            ..
</blockquote>
<blockquote id="blockquote_91">      58... .The judgment in Com Products requires the Defendant to
      prove that the marks must be not merely in use but in &quot;extensive
      use&quot;. Thus, even in interim proceedings, it is not sufficient
      merely for the Defendant to show prima-facie that there is some
      user of the marks. There must be prima facie evidence to show
      extensive use. At the final hearing of the suit the level of proof
      required is higher - the matter requiring to be proved viz.
      &quot;extensive or substantial use&quot; remaining the same.&quot;
</blockquote>
<p id="p_129">60.      Inter alia the appellant submitted that the reliance placed on
behalf of the respondent on the verdicts relied upon are distinguishable
on the facts therein submitted as under:
</p>


<p id="p_130"> CASE LAW 1

 Sun          Pharmaceutical      The competing marks were
 <a href="/doc/157791679/" id="a_22">Industries Limited v. Anglo      OXETOL</a> vs. EXITAL. High Court
 French Drugs &amp; Industries        declined injunction to the Plaintiff.</p><pre id="pre_11">
 Ltd &amp; Anr. (2014) 215 DU
 493 (DB)                         The impugned judgment has been
                                  set aside by the
                                  Hon&#x27;ble Supreme Court in SLP No.




<span class="hidden_text" id="span_63">FAO 447/2018                                                 Page 63 of 87</span>
                             33164 /2014
                            vide order dated 5.07.2016 @ 580-
                            585 Vol. 3

</pre><p id="p_131"> Cited with approval in case Impugned order staved in SLP
 law                       1- 22195/2012- SLP admitted
 Sun
                              C.A. No. 8254 / 2013 Registered
 Pharmaceutical Industries    on 12-09-
</p>
<pre id="pre_12"> <a href="/doc/124691580/" id="a_23">Limited v. West Coast</a>      2013 @586 Vol. 3

 Pharma &amp; Anr

 AIR 2012 Gujarart 142

 CASE LAW 2.

</pre><p id="p_132"> Schering Corporation and The court did not find any
 Ors. v Alkem Laboratories similarity between the trade mark
 Ltd.; 2010                TEMODAL and TEMODAR of the
                           appellants/Plaintiffs         and
 (42) PTC 772 (Del) (DB)   TEMOKEM and TEMOGET of the
                           Defendants.
</p><p id="p_133">                            The court did not consider the
                            aspect of disastrous consequences
                            considering competing drugs
                            were for same ailments, same salt.
</p><p id="p_134">                            Para 2 and 6 Prefix TEMO was
                            taken from the same salt which
                            loas proved to have become
                            publici juris. Para 54

                            In the present case, BEVE in
                            BEVETEX is arbitrary and not
                            derived from the salt Paclitaxel.</p><pre id="pre_13">
                            The competing drugs are for



<span class="hidden_text" id="span_64">FAO 447/2018                                         Page 64 of 87</span>
                                 different      cancers.        and
                                administration of one for another
                                can       lead   to     disastrous
                                consequences.

  CASE LAWS 3.

 Astrazeneca UK Ltd. and        Both parties     were    registered
 Anr. v Orchid Chemicals        proprietor
 and Pharmaceuticals Ltd.;
 (2007) ILR 1 Delhi 874         The court did not find similarity
 (DB)                           between     MEROMER          and
                                MERONEM

                                The court did not consider the
                                aspect of disastrous consequences
                                considering competing drugs
                                were for same ailments, same salt.
                                Prefix MERO was taken from the
                                salt which was proved to be
                                common to trade.


</pre><p id="p_135">61.   Reliance was also placed on behalf of the appellant on a
newspaper article to submit that wrong handing out of drugs by
chemists has resulted into deaths of patients and it has been submitted
on behalf of the appellant that the marks BEVATAS of the respondent
phonetically was similar to the marks BEVETEX of the appellant and
as both the marks of the appellant BEVETEX and the respondent&#x27;s
BEVATAS are used for cure of cancer though it may be for different
kinds of cancer, the similarity between two names of the drugs is
bound to create confusion both to the chemists, to the consumer and to




<span class="hidden_text" id="span_65">FAO 447/2018                                               Page 65 of 87</span>
 those administering the drugs, which can be fatal to the life of a
patient.
</p><p id="p_136">62.   Reliance has also been placed on behalf of the appellant vide
CM No.29182/2019 on the verdict of this Court in Sun Pharma
Laboratories Ltd. Vs. Ajanta Pharma Ltd. in CS (COMM) 622/2018,
a verdict dated 10.05.2019 and in Sun Pharma Laboratories Ltd. Vs.
Intas Pharmaceuticals Limited in CS (COMM) 1206/2016, a verdict
dated 15.05.2019, apart from the appellant also having placed on
record a table of deceptively similar pharmaceutical trade marks as
held vide the verdict of this Court.
</p><p id="p_137">63.   The Sun Pharma Laboratories Ltd. Vs. Ajanta Pharma Ltd.
(supra) refers to the question as to whether the test for infringement
and passing off for nutraceutical products is the same as the test
applicable for pharmaceuticals and related to trade marks &#x27;GLOEYE
and &#x27;GLOTAB both of which were ocular medicines containing plant
extracts and they are termed as &#x27;nutraceuticals&#x27; under <a href="/doc/986267/" id="a_24">Section 22</a> of the
Food Safety and <a href="/doc/79442359/" id="a_25">Standards Act</a>, 2006 and are governed by the Food
Safety and Standards (Licensing and Registration of Food Businesses)
Regulations, 2011and the Food Safety and Standards (Health
Supplements, Nutraceuticals, Food for Special Dietary Use, Food for
Special Medical Purpose, Functional Food and Novel Food)
Regulations, 2016
</p><p id="p_138">64.   The guidelines laid down in Cadila were paraphrased in para 11
thereof to the effect:
</p><blockquote id="blockquote_92">      &quot;i) In the case of drugs, a strict test needs to be applied
      for determining confusion and deception;
</blockquote>



<span class="hidden_text" id="span_66">FAO 447/2018                                               Page 66 of 87</span>
<blockquote id="blockquote_93">       ii) If the products have a difference in composition with
      completely different side effects, a stricter test should be
      applied;
</blockquote><blockquote id="blockquote_94">      iii) Greater vigilance is required where the products are
      meant to cure the same ailments, but the compositions are
      different;
</blockquote><blockquote id="blockquote_95">      iv) Merely because drugs are sold under prescription is
      not sufficient protection against confusion;
</blockquote><blockquote id="blockquote_96">      v) The prevalent social conditions and linguistic barriers
      require stricter measures to be taken, to prevent confusion
      arising from similarity of marks among medicinal
      products;
</blockquote><blockquote id="blockquote_97">      vi) Physicians and pharmacists are not immune to
      mistakes;
</blockquote><blockquote id="blockquote_98">      vii) A lesser degree of proof to establish confusing
      similarity would be required in the case of medicinal
      products as against non- medicinal products;
</blockquote><blockquote id="blockquote_99">      viii) The varying profiles of patients, especially the
      elderly, illiterate persons and children need to be kept in
      mind;
</blockquote><blockquote id="blockquote_100">      ix) In view of public health issues involved in the case of
      medicines, stringent measures ought to be adopted.&quot;
</blockquote>
<p id="p_139">65.   It was submitted on behalf of the appellant that in this case Sun
Pharma Laboratories Ltd. Vs. Ajanta Pharma Ltd. (supra) relied
upon where the two products were used for treating similar medical
conditions it was held that it is not possible to accept the explanation
of the defendant/respondent therein that it was of a bonafide adopter
of the mark. Inter alia reliance was placed on behalf of the appellant
on the verdict in <a href="/doc/125822018/" id="a_26">Laxmikant V. Patel</a> vs. Chetanbhat Shah and Ors.
(2002) (24) PTC 1 (SC) to submit that only the probability of
confusion needs to be considered as laid down by the Hon&#x27;ble
Supreme Court vide para 8 to the effect:
</p>



<span class="hidden_text" id="span_67">FAO 447/2018                                               Page 67 of 87</span>
<blockquote id="blockquote_101">       &quot;8. It is common in the trade and business for a trader or
      a businessman to adopt a name and/or mark under which
      he would carry on his trade or business. According to
      Kerly (Law of Trade Marks and Trade Names, Twelfth
      Edition, para 16.49), the name under which a business
      trades will almost always be a trade mark (or if the
      business provides services, a service mark, or both).
      Independently of questions of trade or service mark,
      however, the name of a business (a trading business or
      any other) will normally have attached to it a goodwill
      that the courts will protect. An action for passing-off will
      then lie wherever the defendant company&#x27;s name, or its
      intended name, is calculated to deceive, and so to divert
      business from the plaintiff, or to occasion a confusion
      between the two businesses. If this is not made out there is
      no case. The ground is not to be limited to the date of the
      proceedings; the court will have regard to the way in
      which the business may be carried on in the future, and to
      its not being carried on precisely as carried on at the date
      of the proceedings. Where there is probability of
      confusion in business, an injunction will be granted even
      though the defendants adopted the name innocently.&quot;
</blockquote>
<p id="p_140">66.   Reliance was also placed on behalf of the appellant on the
observations in the verdict in <a href="/doc/15654482/" id="a_27">Novartis AG vs. Crest Pharma Pvt. Ltd.
and Anr</a>. in CS (OS) 851/2008, a verdict dated 24.07.2009 wherein
vide para 23, it was observed to the effect:
</p><blockquote id="blockquote_102">      &quot;23. The other argument of the counsel for the defendant
      that the plaintiff&#x27;s product is available in tablets and oral
      suspension form and the defendant&#x27;s product is available
      in injection form has also no force as it has been seen
      from experience of the pharmaceuticals products
      available in all over the world that most of the companies
      are making pharmaceuticals products in both the forms
      i.e. tablets as well as in injection form under the same
      trade mark. As per well settled law, the actual confusion




<span class="hidden_text" id="span_68">FAO 447/2018                                                Page 68 of 87</span>
       and deception is not required in order to prove the case of
      passing off even if the defendant has adopted the mark
      innocently and the court comes to the conclusion that the
      two trade marks are deceptively similar, injunction under
      the said circumstances has to be granted. Actual
      deception is not required in an action of passing off.
      <a href="/doc/1181080/" id="a_28">Century Traders v. Roshan Lal Duggar &amp; Co</a>. AIR 1978
      (Del) 250. Therefore there is no chance of confusion and
      deception.&quot;
</blockquote>
<p id="p_141">67.   Inter alia on behalf of the appellant reliance was placed on the
verdict in Sun Pharma Laboratories Ltd. Vs. Ajanta Pharma Ltd.
(supra) wherein it has been categorically laid down therein that in
case of products used for the same ailments but with different
composition, a more stringent test is required to be set down.
</p><p id="p_142">68.   As regard the reliance placed on behalf of the appellant on the
verdict of this Court in <a href="/doc/147593010/" id="a_29">Sun Pharma Laboratories Ltd. vs. Intas
Pharmaceuticals Ltd</a>. in CS (COMM) 1206/2016, a verdict dated
15.05.2019 in which the respondent herein as the defendant of the suit
was injuncted from user of the trade mark DECITAS or any other
mark i.e. similar to the petitioner&#x27;s trade mark &#x27;DECITEX&#x27;, which was
found to be structurally or deceptively similar to the petitioner&#x27;s
registered trade mark &#x27;DECITEX&#x27;, it is essential to observe that the
basic facts in the said case relied upon by the plaintiff therein using
the trade mark DECITEX for its medicinal preparations used for
cancer/chemotherapy since July 2011 with the said trade mark having
been registered on 15.07.2011 with the defendant therein having
alleged that its drug used for cancer/chemotherapy using the trade
mark DECITAS, for which an application for registration was filed on




<span class="hidden_text" id="span_69">FAO 447/2018                                               Page 69 of 87</span>
 19.04.2019 and it was stated that the said trade mark was proposed to
be used.
</p><p id="p_143">69.       It was inter alia observed vide para 17 of the said verdict to the
effect:
</p><blockquote id="blockquote_103">          &quot;17. Hence, the test to see as to whether the trade mark of
          the defendant is deceptively similar to that of the plaintiff
          is as to whether the essential features of the trade mark of
          the plaintiff have been adopted by the defendant. Phonetic
          similarity would constitute an important index. To see as
          to whether a mark bears a deceptive or misleading
          similarity to another, the rival marks have to be compared
          as a whole. All the surrounding circumstances have to be
          considered. Further the competing marks have to be
          compared keeping in mind a unwary purchaser of average
          intelligence and imperfect recollection. In my opinion, the
          mark used by the defendant DECITAS when compared as
          a whole is structurally and phonetically prima facie
          identical and similar to the trade mark of the plaintiff
          DECITEX. That apart, likelihood of confusion in this case
          is much more as the drugs of the respective parties deal
          with the same medical problem i.e. cancer/chemotherapy.
          Strong measures are required to prevent confusion
          arising from similarities of marks in medicines. In my
          opinion, there is no merit in the plea of the defendant that
          the mark of the defendant is not deceptively similar to that
          of the plaintiff.&quot;
</blockquote>
<p id="p_144">It was thus sought to be submitted by the appellant that in the instant
case BEVETEX being the plaintiff&#x27;s mark and BEVATAS being the
respondent&#x27;s marks, the facts of the instant case are in pari materia
with the facts of the case in Sun Pharma Laboratories Ltd. Vs. Intas
Pharmaceuticals Ltd. with the mark of the appellant herein being
BEVETEX and that of the respondent being BEVATAS.
</p>



<span class="hidden_text" id="span_70">FAO 447/2018                                                    Page 70 of 87</span>
<p id="p_145"> 70.   Through the written submissions submitted on behalf of the
respondent, the submissions that were made through the written
statement of the respondent as defendant in TM No.146/2018 have
been reiterated. It was further submitted through the written
submissions that there was no similarity in both the marks
&quot;BEVETEX&quot; and &quot;BEVATAS&quot; which are entirely different and there
is no likelihood of confusion or deception and/or similarity between
the two marks amongst the customers and that the two marks are
totally different, dissimilar and distinct and that there cannot be any
likelihood of confusion and that the said marks are visually and
phonetically dissimilar. The respondent no.2 further submitted that
even the drugs which are sold under these marks are administered
under supervision of specialists in a different ways and there is no
likelihood of confusion at any level and in the instant case, the marks
are visually, structurally and phonetically different:
</p><p id="p_146">71.   The respondent has further submitted that the respondent had
also applied for the registration of its trade mark vide application
bearing No. 3254683 dated 09.05.2016 and that that the respondent&#x27;s
Trade Mark when examined by the Examiner of Trade marks, he did
not cite any conflicting trademark and the application was accepted for
advertisement and even the trademarks office did not find any
similarity between the trademarks of the appellant&#x27;s and of the
respondent&#x27;s. The respondent has further submitted that the appellant
was    manufacturing      a    medicine     containing   Molecule/Salt
PACLITAXEL under the mark BEVETEX as a scheduled drug for
treatment of Breast Cancer, Non-small Lung cancer and pancreatic



<span class="hidden_text" id="span_71">FAO 447/2018                                               Page 71 of 87</span>
 cancer and that the appellant alleges to have started selling its
medicine under the mark BEVETEX since the year 2015 though the
appellant has claimed to have invented the mark in year 1983 and that
the appellant has malafidely hoarded the said mark and that the
appellant has no alleged goodwill or recognition with the mark as the
same has been very recently adopted.
</p><p id="p_147">72.   The respondent has further submitted that both the products
were launched within a span of one year and the appellant has failed to
prove that the appellant&#x27;s trade mark has attained the reputation and
goodwill as to fall in the category of a well-known trade mark and that
the turnover of the respondent&#x27;s product BEVETAS is more than that
of the appellant and it cannot thereby be said that respondent is trying
to encash upon the reputation and goodwill of the appellant&#x27;s trade
mark. The respondent has further submitted that the appellant is a
subsidiary of Sun Pharmaceuticals Industries Limited and the mark
was initially filed for registration vide application No. 410744 dated
16.09.1983 on &quot;PROPOSED TO BE USED BASIS&quot; under the
proprietorship of TAMILNADU DADHA PHARMACEUTICALS
LTD. and later allegedly transferred to Sun Pharmaceuticals Industries
Limited, who further transferred it in the name of the appellant. The
respondent has further submitted that no documents to the effect of
transfer have either been placed on record by the appellant nor are
they available on the website of the Trade Mark registry.
</p><p id="p_148">73.   The respondent has further submitted through its written
submissions that the process of infusion is a half or full day process,
depending upon the medical condition of the patient and that



<span class="hidden_text" id="span_72">FAO 447/2018                                                Page 72 of 87</span>
 &quot;Intravenous Product&quot; and cannot be self-administered and the entire
process of infusion is done under constant monitoring, guidance and
supervision of super specialists and that Medical practitioners
prescribing or administering the drug are super specialists like
oncologists and radiologists and can be administered under their
supervision though specialized producers by trained and skilled
personnel within oncology centers. The respondent no.2 has further
submitted that the respondent&#x27;s drug costs three times the drug of the
appellant and that the drug of the respondent is a biological/biosimilar
drug which involves an extremely expensive clinical trial.
</p><p id="p_149">74.   Inter alia the respondent no.2 has further submitted that there
was no prima facie case whatsoever made out for the grant of the
interim injunction as prayed by the appellant and thus had rightly not
been granted by the learned trial Court and that there was no prima
facie evidence to show that appellant&#x27;s mark has acquired goodwill
and reputation and that rather the respondent&#x27;s brand has acquired
huge reputation and goodwill in the short span of time and the clear
motive of the appellant by filing the litigation was to curb healthy
competition in the market. The respondent has further submitted that
the launch of the respondent&#x27;s drug was aimed at making
BEVACIZUMAB accessible for Indian patients and that before the
launch of BEVATAS 400 mg, only approx. 200 patients per month
could afford the Bevacizumab therapy, however, now there has been a
phenomenal increase and roughly 700 patients get benefited of which
BEVETAS is the most preferred product.
</p>



<span class="hidden_text" id="span_73">FAO 447/2018                                                 Page 73 of 87</span>
<p id="p_150"> 75.   The respondent has further submitted that the product of the
respondent is in the market for such a long period and has created its
own goodwill and reputation over all these years and that the product
of the respondent is a lifesaving drug, essential for cancer treatment
and has proved its success and has a large reach to the number of
ailing patients across the length and breadth of the country and with
offerings of the respondent such number of patients are on rise. The
respondent has further submitted that the respondent&#x27;s product is
highly efficacious and also affordable (approx. 60% less) which is
making more and more number of ailing eligible patients to be
benefited by the said therapy and that thus, the continuity of
BEVETAS therapy is of paramount importance for survival of patients
and that if the injunction is granted it shall cause great injury to the
cancer patients in India. The respondent has further submitted that the
marks BEVETEX and BEVATAS are totally different, dissimilar and
distinct and that the drug formulations of the marks are completely
different along with mode of administration and that there cannot be
likelihood of confusion as these drugs are Schedule H drugs and
cannot be sold off the shelf and the indications and effect of both the
drugs are different and is known to the experts and medical
practitioners who prescribe these drugs.
</p><p id="p_151">76.   The respondent further submitted that the appellant had
contended in the plaint that there is likelihood of confusion between
the marks, however, in the rejoinder to the application under Order 39
Rule 1 and 2 the appellant suddenly shifted its stand in making a bald
misleading averment of actual confusion having taken place and that



<span class="hidden_text" id="span_74">FAO 447/2018                                               Page 74 of 87</span>
 the appellant has failed to file any documentary proof establishing an
instance of actual confusion. The respondent has further submitted that
the appellant has approached this Court with unclean hands and has
suppressed the relevant information and that the appellant filed the
notice of opposition against the trademark application of the
respondent on 27.12.2016 and the respondent filed the detailed
response to the same on 28.03.2017. The respondent has further
submitted that the respondent had launched its drug in October 2016
and the said launch was extensively covered in media, and, therefore,
the appellant has been well aware of the respondent since 2016. The
respondent further submitted that the appellant has blatantly lied and
has filed the present suit on a frivolous cause of action with an ill
motive to deprive the respondent of its lawful right.
</p><p id="p_152">77.   The respondent further submitted that there is no cause of action
for the institution of the present suit and that the appellant has claimed
that the cause of action for institution of the present suit arose in the
third week of December and more specifically on 20.12.2017,
however, the appellant had opposed the respondent&#x27;s trade mark
application in 2016 and further the launch of the respondent&#x27;s drug
was in 2016 and that the appellant has been well aware of the same
and had approached the Court with unclean hands. The respondent has
further submitted that the appellant has its registered office and
principal place of business at Mumbai and the respondent has its
registered office and place of business at Ahmedabad, Gujarat and
thus, the territorial jurisdiction of this Court has not been made out by
the appellant and the appellant is in fact attempting to indulge in



<span class="hidden_text" id="span_75">FAO 447/2018                                                 Page 75 of 87</span>
 forum shopping and has filed the present suit and application just to
harass the respondent.
</p><p id="p_153">78.    Reliance was placed on behalf of the respondent on the
following verdicts:
</p>


<pre id="pre_14">      S.No. Case Name          Citation         Relevant
                                                Paragraphs

      1.       Sun             (2014) 215 DLT Para No. 16,
               Pharmaceutical                 17, 18, 19, 20
               Industries Ltd. 493 (DB)
               &amp; Anr. Vs.
               Anglo French
               Drugs        &amp;
               Industries Ltd.
               Anr.

      2.       Schering         2010(5) RA.J.   Para No. 21,
               Corporation &amp;                    22, 23, 30, 61,
               Ors. Vs. Alkem 501 (Del);        62, 63,
               Laboratories
                                2009(165) DLT
               Ltd.
                                474; 2010(42)
               And
                                PTC 772
               Schering                         100,102
               Corporation &amp;
               Ors. Vs. Getwell
               Life    Sciences
               India Pvt. Ltd.

      3.       Astrazeneca UK (2007) ILR 1      Para No. 19,
               Limited &amp; Anr.                   20, 21, and 22
               Vs.      Orchid DeM874; 2007




<span class="hidden_text" id="span_76">FAO 447/2018                                              Page 76 of 87</span>
                Chemicals and (34)            PTC
               Pharmaceuticals 469(del)
               Ltd.

<span class="hidden_text" id="span_77">      4.       Gufic Ltd. and 2010 (43) PTC Para No. 22, 23</span>
               Anr.          Vs. 788 (Del)
               Clinique                     and 24
               Laboratories,
               LLC and Anr.

</pre><p id="p_154">79.    It has been submitted on behalf of the respondent that reliance
placed on behalf of the appellant on the verdicts of this Court in Sun
Pharma Laboratories Ltd. Vs. Ajanta Pharma Ltd. (supra) and Sun
Pharma Laboratories Ltd. Vs. Intas Pharmaceuticals Limited (supra)
is misplaced as the facts of those cases are distinguishable and not in
pari materia to the facts of the instant case.
</p><p id="p_155">80.    On a consideration of the rival submissions that have been made
on behalf of either side, it is essential to observe that the suit in which
the appellant herein has had filed the application seeking an interim
restraint against the respondent is not merely for a restraint against
infringement of trade mark but also for a restraint against passing off
of the goods of the respondent claimed to be deceptively similar with
the plaintiff&#x27;s/ appellant&#x27;s trade mark of BEVETEX, the respondent&#x27;s
trade mark being BEVATAS. Thus it cannot be contended on behalf
of the appellant/ plaintiff that the suit being only one for an action for
infringement, the relevant consideration is only the similarity of the
essential features of the registered trade mark and the impugned trade
mark as opposed to an action for passing of where the defendant can
escape the liability by showing dis-similar features nor can it be



<span class="hidden_text" id="span_78">FAO 447/2018                                                  Page 77 of 87</span>
 contended that the difference between the appellant&#x27;s mark and the
respondent&#x27;s mark are irrelevant.
</p><p id="p_156">81.   The sample of the original packaging and trade dress in the
instant case were submitted before this Court by either side on
04.10.2018. The said sample of the appellant is to the effect:
</p>



<span class="hidden_text" id="span_79">FAO 447/2018                                                Page 78 of 87</span>
<span class="hidden_text" id="span_80"> FAO 447/2018   Page 79 of 87</span>
<p id="p_157"> and the sample of the respondent&#x27;s product is to the effect:
</p>



<span class="hidden_text" id="span_81">FAO 447/2018                                                   Page 80 of 87</span>
<p id="p_158"> 82.   As observed vide the impugned order vide para 7 thereof that
there is no ocular/visual similarity whatsoever in the trade mark of the
appellant and the respondent prima facie. The said observations of the
impugned order have already been adverted to elsewhere hereinabove.
</p><p id="p_159">83.   The impugned order also appropriately holds that there is no
phonetic similarity in the two words BEVETEX and BEVATAS as
pronounced as a whole and do not rhyme with each other. Thus prima
facie the product trade dress of both products of the appellant and of
the respondent do not appear to be even remotely similar nor
confusing to even a layman nor is there phonetic similarity sufficiently
enough to be confusing to any consumer of the products.
</p><p id="p_160">84.   Furthermore, both the drugs BEVETEX of the appellant and
the drug BEVATAS of the respondent are schedule H, IV injection
drug and cannot be self-administered and are not over the counter
drugs nor easily readily available for self-medication and can be
administered to patients only by highly specialized, super specialized
oncologists    and     under   their   supervision   through    specialized
procedures by trained and skilled personnel within an oncology centre.
Furthermore, the two products are also sold under different
contents/weight with different prices being to the effect:
</p><pre id="pre_15">                (i)      BEVATAS - 400 mg cost : Rs.39,995/-
                                   100 mg cost : Rs.25,990/-
                (ii)     BEVETEX - 300 mg cost : Rs.37,000/-
                                  -100 mg cost :Rs. 32,500/-

</pre><p id="p_161">85.   In as much as the consumers and customers of the products of
the appellant and the respondents are not unwary customers and




<span class="hidden_text" id="span_82">FAO 447/2018                                                   Page 81 of 87</span>
 illiterate persons and not layman and are rather highly specialized
oncologists and a specialized medical staff, there appears no
likelihood of any confusion. The two drugs are used for different
indications of which, the specialist oncologists have complete
information, knowledge and are aware of the same as rightly observed
vide the impugned order vide para 13 thereof.
</p><p id="p_162">86.     The drugs can also only be administered through the
intravenous mode and self-administration is not possible and can only
be administered through constant monitoring, guidance and under
supervision of the super specialists and thus there appears no
likelihood of any confusion or deception for administration of a wrong
drug.
</p><p id="p_163">87.     It is essential to observe that each case is to be determined on its
own facts and circumstances and thus the reliance placed on behalf of
the appellant on a catena of verdicts relied upon in the facts and
circumstances of the instant case does not aid the appellant in as much
as observed by the Hon&#x27;ble Division Bench of this Court in <a href="/doc/157791679/" id="a_30">Sun
Pharmaceutical Industries Ltd. &amp; Anr. vs. Anglo Frensh Drgus &amp;
Industries Ltd. &amp; Anr</a>. 2014 SCC OnLine Del 4716 vide para 18
thereof, the verdict of the Hon&#x27;ble Supreme Court in Cadila (Supra)
has to be read in its entirety and the contours of the test laid down by
the Hon&#x27;ble Supreme Court thereby cannot be restricted by an
artificial process which focuses attention only upon the factual aspect
of both products being pharmaceutical preparations and that the
observations in para 42 of the said verdict, which has already been
adverted to elsewhere hereinabove, thus as laid down by the Hon&#x27;ble



<span class="hidden_text" id="span_83">FAO 447/2018                                                   Page 82 of 87</span>
 Supreme Court in Cadila (Supra) that the weightage to be given to
each of the factors in relation to the aspect of resembleness between
the marks, phonetically similar and hence similar in idea; nature of the
goods in respect of which they are used as trade marks, similarity in
the nature character and performance of the goods of the rival traders,
the class of purchasers who are likely to buy the goods bearing the
marks and the education and intelligence and a degree of care they
required and likely to exercise in purchasing and/or using the goods
and other surrounding circumstances which may be relevant in the
extent of dissimilarity between the competing marks have to be
considered in each and every case.
</p><p id="p_164">88.   The other aspect which cannot be overlooked is that the
respondent&#x27;s trade mark has been derived by combining publici-juris
i.e. the abbreviation of the salt &#x27;Bevacizumab with the suffix TAS, the
abbreviated form of its trade/company name and there is prima facie
presently nothing to indicate that the appellant/ plaintiff has any
exclusive right to use the abbreviation of BEVE which it has
arbitrarily utilized in relation to the compound / salt with Paclitaxel.
The appellant/ plaintiff has thus added the suffix BEVE to the word
TEX to arrive at its trade mark BEVETEX and the respondent /
defendant has on the other hand added the suffix TAS which is a part
of its company named INTAS to arrive at the trade mark BEVATAS
and as observed hereinabove the user of the word BEVA by the
respondent being only descriptive and publici juris, in as much as the
abbreviated prefix BEVA is used for several drugs by several
prominent pharmaceutical industrialists other than the respondent i.e.



<span class="hidden_text" id="span_84">FAO 447/2018                                               Page 83 of 87</span>
 BEVACIRE of Reliance, BEVAZZA of Lupin, BEVAREST of
Emcure and ZYBEV of Zydex US. Furthermore, as put forth on behalf
of the respondent that several trademarks have used the prefix of BEV
in the pharmaceutical trade which are already registered, as under:-
</p>
<pre id="pre_16">   S.NO.       APPLICATION NO.                   MARK
   1.          340724                            BEVARATE
   2.          373052                            BEVISAR
   3.          451957                            BEVIN
   4.          713912                            BEVENT
   5.          792186                            BEVIZ
   6.          890171                            BEVAC- A
   7.          902979                            BEVITAL
   8.          927555                            BEVAXIM
   9.          1169016                           BEVAL
   10.         1195752                           BEVON


</pre><p id="p_165">and thus it is submitted on behalf of the respondent that there cannot
be a monopoly over a particular word which is a general word and
which is used by several companies.
</p><p id="p_166">89.      Furthermore, the word suffice TAS is associated which a large
number of products of the respondent /defendant which has been
amalgamated with the name of the molecule / ingredient or salt
registered in the name of the respondent / defendant.
</p>



<span class="hidden_text" id="span_85">FAO 447/2018                                               Page 84 of 87</span>
<p id="p_167"> 90.   Furthermore, presently, the appellant though it applied for
registration of the mark BEVETEX in the year 1993, which was
granted to it in the year 1999 and began its utilization only in the year
2015 and despite having learnt of the launch of the defendant&#x27;s drug in
2016 by having opposed the trade mark application of the defendant /
respondent in the year 2016 having chosen to institute the suit by
claiming that the cause of the action for the suit arose only on 20 th
December, 2017, the contention of the respondent that the suit of the
plaintiff/ appellant suffered from delay, laches would essentially have
to be considered during the trial. Undoubtedly, drugs are not sweets
but poison as observed by the Hon&#x27;ble Supreme Court in Cadila
(supra) as contended on behalf of the appellant, however as observed
elsewhere hereinabove as laid down also in <a href="/doc/157791679/" id="a_31">Sun Pharmaceutical
Industries Ltd. &amp; Anr. vs. Anglo Frensh Drgus &amp; Industries Ltd. &amp;
Anr</a>. (supra) by the Hon&#x27;ble Division Bench of this Court vide para 18
thereof, the verdict of the Hon&#x27;ble Supreme Court in Cadila (supra)
has to be read in its entirety and each case is to be determined on its
own facts and circumstances.
</p><p id="p_168">91.   Undoubtedly as laid down in paraphrasing of the tests laid down
in Cadila (supra) in para 11.6 in Sun Pharma Laboratories Ltd. Vs.
Ajanta Pharma Ltd. in CS (COMM) 622/2018 physicians and
pharmacists are not immune to mistake, yet it cannot be overlooked
that in the instant case, the administration of the drug has to be
intravenous    by specialized oncologists by a special procedure by
trained medical staff and both the products of the appellant and of the




<span class="hidden_text" id="span_86">FAO 447/2018                                                Page 85 of 87</span>
 respondent through their trade dress cannot even remotely be prima
facie considered to be similar.
</p><p id="p_169">92.   In the circumstances, as rightly held by the learned trial Court
vide the impugned order dated 17.09.2018, there is no prima facie case
brought forth in favour of the appellant for the grant of the interim
injunction seeking a restraint against the respondent for user of its
trade mark BEVETEX on the ground of stated similarity or deceptive
similarity with the trade mark of the appellant/plaintiff BEVETEX
which prima facie does not appear to exist. As rightly observed vide
the impugned order dated 17.09.2018, there is no balance of
convenience in favour of the appellant/ plaintiff also in as much as the
appellant has not been able to prima facie establish that its trademark
BEVETEX has acquired a reputation and goodwill so as to fall in the
category of a well known trademark and thus in the circumstances,
there is prima facie no irreparable injury likely to be caused to the
plaintiff by the user of the impugned mark by the defendant.
</p><p id="p_170">93.   It is also essential to observe that as laid down by the Hon&#x27;ble
Supreme Court in Wander Ltd. and Ors. Vs. Antox India P. Ltd.
1990(2) ARBLR 399 (SC), the Appellate Court is not to re-assess the
material and seek to reach to a conclusion different from the one
reached by the Court below if one reached by that Court was
reasonably possible on the material available and the Appellate Court
would not normally be justified in interfering with the exercise of
discretion under appeal solely on the ground that if it had considered
the matter at the trial stage it would have come to contrary conclusion
and that if the discretion that has been exercised by the learned trial



<span class="hidden_text" id="span_87">FAO 447/2018                                               Page 86 of 87</span>
 Court has been reasonably exercised and in a judicial manner that the
Appellate Court may or would have taken a different view, may not
justify interference with the trial Court&#x27;s exercise of discretion. In the
instant case, as it is apparent, it cannot be contended on behalf of the
appellant that there has been an unreasonable or un-judicious exercise
of discretion by the learned trial Court vide the impugned order dated
17.09.2018 in the non-grant of the prayer for the ad interim injunction
as prayed by the appellant in TM No.146/2017.
</p><p id="p_171">94.   In the circumstances, there is no merit in the appeal against the
said impugned order, which is thus dismissed.
</p>

<p id="p_172">                                                 ANU MALHOTRA, J
               th
JANUARY 9 , 2020/mk/vm




<span class="hidden_text" id="span_88">FAO 447/2018                                                 Page 87 of 87</span>
 </p>